SelectQuote (SLQT) 10-Q 5 May 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2022	Apr. 30, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39295
Entity Registrant Name	SelectQuote, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3339273
Entity Address, Address Line One	6800 West 115th Street
Entity Address, Address Line Two	Suite 2511
Entity Address, City or Town	Overland Park
Entity Address, State or Province	KS
Entity Address, Postal Zip Code	66211
City Area Code	913
Local Phone Number	599-9225
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	SLQT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		164,401,645
Entity Central Index Key	0001794783
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 199,359	$ 286,454
Accounts receivable	168,735	105,298
Commissions receivable-current	77,158	89,120
Other current assets	13,246	4,486
Total current assets	458,498	485,358
COMMISSIONS RECEIVABLE—Net	761,138	756,777
PROPERTY AND EQUIPMENT—Net	45,558	29,510
SOFTWARE—Net	15,558	12,611
OPERATING LEASE RIGHT-OF-USE ASSETS	29,018	31,414
INTANGIBLE ASSETS—Net	36,022	40,670
GOODWILL	73,732	68,019
OTHER ASSETS	15,790	1,436
TOTAL ASSETS	1,435,314	1,425,795
CURRENT LIABILITIES:
Accounts payable	27,445	34,079
Accrued expenses	35,593	20,676
Accrued compensation and benefits	46,229	40,909
Operating lease liabilities—current	5,181	5,289
Current portion of long-term debt	7,169	2,360
Other current liabilities	2,079	5,504
Total current liabilities	123,696	108,817
LONG-TERM DEBT, NET—less current portion	699,386	459,043
Deferred income taxes	76,806	139,240
OPERATING LEASE LIABILITIES	35,301	38,392
OTHER LIABILITIES	3,533	11,743
Total liabilities	938,722	757,235
COMMITMENTS AND CONTINGENCIES (Note 8)
SHAREHOLDERS’ EQUITY:
Common stock, $0.01 par value	1,644	1,635
Additional paid-in capital	554,045	544,771
Retained earnings (accumulated deficit)	(68,684)	121,925
Accumulated other comprehensive income	9,587	229
Total shareholders’ equity	496,592	668,560
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,435,314	$ 1,425,795

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common stock, par value, (dollars per share)	$ 0.01	$ 0.01

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
REVENUE:
Total revenue	$ 275,113	$ 265,346	$ 627,621	$ 745,685
OPERATING COSTS AND EXPENSES:
Cost of revenue	119,459	71,439	359,732	206,605
Marketing and advertising	125,082	116,690	409,005	298,696
General and administrative	21,031	19,251	64,570	44,496
Technical development	6,436	4,860	18,675	13,458
Total operating costs and expenses	272,008	212,240	851,982	563,255
INCOME (LOSS) FROM OPERATIONS	3,105	53,106	(224,361)	182,430
INTEREST EXPENSE, NET	(12,179)	(7,355)	(31,300)	(20,898)
LOSS ON EXTINGUISHMENT OF DEBT	0	(3,315)		(3,315)
OTHER EXPENSES, NET	(23)	(349)	(177)	(1,545)
INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT)	(9,097)	42,087	(255,838)	156,672
INCOME TAX EXPENSE (BENEFIT)	(2,649)	6,852	(65,229)	31,846
NET INCOME (LOSS)	$ (6,448)	$ 35,235	$ (190,609)	$ 124,826
NET INCOME (LOSS) PER SHARE:
Basic (in dollars per share)	$ (0.04)	$ 0.21	$ (1.16)	$ 0.77
Diluted (in dollars per share)	$ (0.04)	$ 0.21	$ (1.16)	$ 0.75
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:
Basic (in shares)	164,083	163,023	163,914	162,705
Diluted (in shares)	164,083	165,731	163,914	165,495
OTHER COMPREHENSIVE INCOME, NET OF TAX:
Gain on cash flow hedge	$ 7,589	$ 1,810	$ 9,358	$ 1,669
OTHER COMPREHENSIVE INCOME	7,589	1,810	9,358	1,669
COMPREHENSIVE INCOME (LOSS)	1,141	37,045	(181,251)	126,495
Commission
REVENUE:
Total revenue	222,538	235,216	495,494	660,631
Production bonus and other
REVENUE:
Total revenue	$ 52,575	$ 30,130	$ 132,127	$ 85,054

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Restricted Stock Units (RSUs)	Common Stock	Common StockRestricted Stock Units (RSUs)	Additional Paid-In Capital	Additional Paid-In CapitalRestricted Stock Units (RSUs)	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Jun. 30, 2020			162,191,000
Beginning balance at Jun. 30, 2020	$ 544,186		$ 1,622		$ 548,113		$ (4,295)	$ (1,254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	124,826						124,826
Gain on cash flow hedge, net of tax	1,301							1,301
Amount reclassified into earnings, net of tax	368							368
Stock options exercised (in shares)			1,135,000
Stock options exercised	(9,233)		$ 11		(9,244)
Issuance of common stock pursuant to employee stock purchase plan (in shares)			56,000
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	986		$ 1		985
Share-based compensation expense	3,670				3,670
Ending balance (in shares) at Mar. 31, 2021			163,382,000
Ending balance at Mar. 31, 2021	666,104		$ 1,634		543,524		120,531	415
Beginning balance (in shares) at Jun. 30, 2020			162,191,000
Beginning balance at Jun. 30, 2020	544,186		$ 1,622		548,113		(4,295)	(1,254)
Ending balance (in shares) at Jun. 30, 2021			163,510,000
Ending balance at Jun. 30, 2021	668,560		$ 1,635		544,771		121,925	229
Beginning balance (in shares) at Dec. 31, 2020			162,774,000
Beginning balance at Dec. 31, 2020	630,970		$ 1,628		545,441		85,296	(1,395)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	35,235						35,235
Gain on cash flow hedge, net of tax	1,675							1,675
Amount reclassified into earnings, net of tax	135							135
Stock options exercised (in shares)			552,000
Stock options exercised	(4,326)		$ 5		(4,331)
Issuance of common stock pursuant to employee stock purchase plan (in shares)			56,000
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	986		$ 1		985
Share-based compensation expense	1,429				1,429
Ending balance (in shares) at Mar. 31, 2021			163,382,000
Ending balance at Mar. 31, 2021	666,104		$ 1,634		543,524		120,531	415
Beginning balance (in shares) at Jun. 30, 2021			163,510,000
Beginning balance at Jun. 30, 2021	668,560		$ 1,635		544,771		121,925	229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(190,609)						(190,609)
Gain on cash flow hedge, net of tax	8,844							8,844
Amount reclassified into earnings, net of tax	$ 514							514
Stock options exercised (in shares)	350,222		349,000
Stock options exercised	$ 1,296		$ 3		1,293
Issuance of common stock pursuant to employee stock purchase plan (in shares)			466,000
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	1,882		$ 5		1,877
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings (in shares)				76,000
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings		$ (147)	$ 1			$ (148)
Share-based compensation expense	6,252				6,252
Ending balance (in shares) at Mar. 31, 2022			164,401,000
Ending balance at Mar. 31, 2022	496,592		$ 1,644		554,045		(68,684)	9,587
Beginning balance (in shares) at Dec. 31, 2021			164,013,000
Beginning balance at Dec. 31, 2021	492,404		$ 1,640		551,002		(62,236)	1,998
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(6,448)						(6,448)
Gain on cash flow hedge, net of tax	7,421							7,421
Amount reclassified into earnings, net of tax	168							168
Stock options exercised (in shares)			10,000
Stock options exercised	14		$ 0		14
Issuance of common stock pursuant to employee stock purchase plan (in shares)			376,000
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	893		$ 4		889
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings (in shares)				2,000
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings		$ (3)				$ (3)
Share-based compensation expense	2,143				2,143
Ending balance (in shares) at Mar. 31, 2022			164,401,000
Ending balance at Mar. 31, 2022	$ 496,592		$ 1,644		$ 554,045		$ (68,684)	$ 9,587

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (6,448)	$ 35,235	$ (190,609)	$ 124,826
Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities:
Depreciation and amortization			17,957	11,260
Loss on disposal of property, equipment, and software	384	101	741	261
Share-based compensation expense			6,252	3,689
Deferred income taxes			(65,623)	31,702
Amortization of debt issuance costs and debt discount			4,217	2,482
Write-off of debt issuance costs			0	2,570
Fair value adjustments to contingent earnout obligations		334	0	1,487
Non-cash lease expense			3,065	2,869
Changes in operating assets and liabilities:
Accounts receivable			(62,803)	(49,224)
Commissions receivable			7,601	(251,188)
Other assets			(8,275)	4,349
Accounts payable and accrued expenses			8,096	26,223
Operating lease liabilities			(3,868)	(2,631)
Other liabilities			(1,113)	30,378
Net cash used in operating activities			(284,362)	(60,947)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(24,515)	(6,520)
Purchases of software and capitalized software development costs			(7,570)	(5,807)
Acquisition of business			(6,927)	(23,879)
Investment in equity securities			(1,000)	0
Net cash used in investing activities			(40,012)	(36,206)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit			50,000	0
Payments on Revolving Credit Facility			(50,000)	0
Net proceeds from Term Loans			242,000	0
Payments on DDTL Facility			(613)	0
Net proceeds from Term Loans			0	228,753
Payments on Term Loans			(1,180)	(84,118)
Payments on other debt			(130)	(189)
Proceeds from common stock options exercised and employee stock purchase plan	900	1,400	3,179	1,778
Payments of tax withholdings related to net share settlement of equity awards			(148)	(10,026)
Payments of debt issuance costs			(328)	(885)
Payment of contingent earnout liability			0	32,300
Payment of acquisition holdback			(5,501)	0
Net cash provided by financing activities			237,279	97,331
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			(87,095)	178
CASH AND CASH EQUIVALENTS—Beginning of period			286,454	368,870	$ 368,870
CASH AND CASH EQUIVALENTS—End of period	$ 199,359	$ 369,048	199,359	369,048	$ 286,454
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid, net			(27,010)	(18,309)
Income taxes paid, net			(67)	(121)
Private Placement
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs			0	(1,771)
IPO
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs			$ 0	$ (3,911)

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES Description of Business —SelectQuote, Inc. (together with its subsidiaries, the “Company” or “SelectQuote”) contracts with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. The Company obtains leads from, among other sources, InsideResponse, a wholly-owned subsidiary that provides sales leads to the consumer insurance industry. The Company also coordinates various healthcare-related services through its Population Health platform, which includes SelectRx, a closed-door, long-term care pharmacy that offers pharmacy services, including essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services under the Patient Centered Pharmacy Home (PCPH) model. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products, and along with Population Health and InsideResponse, is referred to as “Senior”. SelectQuote’s Life division (“Life”) sells term life, final expense, and other ancillary products, and SelectQuote’s Auto & Home division (“Auto & Home”) primarily sells non-commercial auto and home property and casualty insurance products. SelectQuote’s licensed insurance agents provide comparative rates from a variety of insurance carriers relying on our technology distribution channel with a combination of proprietary and commercially available software to perform its quote service and sell insurance policies on behalf of the insurance carriers. The Company primarily earns revenue in the form of commission payments from the insurance carriers. Commission payments are received both when the initial policy is sold (“first year”) and when the underlying policyholder renews their policy in subsequent years (“renewal”). The Company also receives certain volume-based bonuses from some carriers on first-year policies sold based on attaining various predetermined target sales levels or other agreed upon objectives. These bonuses are referred to as “production bonuses” or “marketing development funds.” Additionally, the Company earns revenue from its Population Health platform, mail-order prescription revenue from SelectRx, and lead generation revenue from InsideResponse. Basis of Presentation —The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC (“SQAH”), ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC, and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our A nnual Report on Form 10-K for the year ended June 30, 2021, as amended by the Form 10-K/A filed with the SEC on February 14, 2022 (the “2021 Annual Report”) and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2022, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2021. Certain reclassifications have been made to prior periods to conform with current year presentation. Use of Estimates —The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of revenue recognition, accounts receivable, commissions receivable, the provision for income taxes, share-based compensation, and valuation of intangible assets and goodwill. The impact of changes in estimates is recorded in the period in which they become known. Going Concern —The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. Under the Senior Secured Credit Facility, the Company is required to maintain a certain asset coverage ratio, as discussed further in Note 7 to the condensed consolidated financial statements. As of March 31, 2022, the Company is in compliance with all of its debt covenants; however, our financial projections indicate that, based on our current business plan, we will not maintain the required asset coverage ratio within one year after the date that the condensed consolidated financial statements are issued. Failure to maintain the required ratio would constitute a violation of our obligations under the Senior Secured Credit Facility and would permit our lenders to declare us in default. In the event of a default, our lenders could accelerate all amounts owing under the Senior Secured Credit Facility. We do not currently have sufficient liquidity to repay such indebtedness. We have commenced discussions of a covenant waiver or modification with our lenders; however, the Company cannot provide any assurances that it will be successful in obtaining such a waiver or modification on acceptable terms, or at all. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Seasonality —Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period (“AEP”), which runs from October through December each year, and are allowed to switch plans from an existing plan during the open enrollment period (“OEP”), which runs from January through March each year. As a result, commission revenue for our Senior segment is highest in the second quarter and to a lesser extent, the third quarter during OEP. Most policies sold during AEP are effective as of and renew annually on January 1. Significant Accounting Policies —There have been no material changes to the Company’s significant accounting policies as described in our 2021 Annual Report. Recent Accounting Pronouncements Not Yet Adopted —In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if the acquirer had originated the contracts. Prior to this ASU, an acquirer generally recognizes contract assets acquired and contract liabilities assumed that arose from contracts with customers at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of the amendment (or if adopted early as of an interim period, as of the beginning of the fiscal year that includes the interim period of early application). The Company will continue to evaluate the impact of this guidance, which will depend on the contract assets and liabilities acquired in future business combinations. Recent Accounting Pronouncements Adopted —In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies and changes the accounting for certain income tax transactions, among other minor improvements. This standard was effective for the Company on July 1, 2021, and did not have a material impact on the condensed consolidated financial statements and related disclosures. Immaterial Correction of Prior Period Financial Statements —Subsequent to the issuance of the Company’s financial statements as of and for the year ended June 30, 2021 and as previously disclosed in our Form 10-Q for the three and six months ended December 31, 2021, the Company discovered that the provision for first year commission revenue for certain final expense policies offered by one of its insurance carrier partners should have been accrued based on a higher lapse rate. The error in the lapse rate resulted in commission revenue being misstated by $6.1 million and $2.0 million, for the years ended June 30, 2021 and 2020, and $2.4 million for the three months ended September 30, 2021, respectively. Accounts receivable was misstated by $8.1 million and $2.0 million as of June 30, 2021 and 2020, respectively. The impact of the error on net income for the year ended June 30, 2021, was a decrease of $4.8 million. Management evaluated this misstatement and concluded it was not material to prior periods, individually or in aggregate. However, correcting the cumulative effect of the error in the three and six months ended December 31, 2021, would have had a significant effect on the results of operations. Therefore, the Company elected to correct the relevant prior period condensed consolidated financial statements and related footnotes for this error for comparative purposes. The following tables reflect the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated financial statements presented in this Form 10-Q: CORRECTED CONDENSED CONSOLIDATED BALANCE SHEET (unaudited) June 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Accounts receivable $ 113,375 $ (8,077) $ 105,298 Total current assets 493,435 (8,077) 485,358 Total assets 1,433,872 (8,077) 1,425,795 Deferred income taxes 140,988 (1,748) 139,240 Total liabilities 758,983 (1,748) 757,235 Retained earnings (accumulated deficit) 128,254 (6,329) 121,925 Total shareholders’ equity 674,889 (6,329) 668,560 Total liabilities and shareholders’ equity $ 1,433,872 $ (8,077) $ 1,425,795 CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended March 31, 2021 Nine Months Ended March 31, 2021 (in thousands) As Previously Reported Adjustment As Corrected As Previously Reported Adjustment As Corrected Commission revenue $ 236,793 $ (1,577) $ 235,216 $ 664,312 $ (3,681) $ 660,631 Total revenue 266,923 (1,577) 265,346 749,366 (3,681) 745,685 Income (loss) from operations 54,683 (1,577) 53,106 186,111 (3,681) 182,430 Income (loss) before income tax expense (benefit) 43,664 (1,577) 42,087 160,353 (3,681) 156,672 Income tax expense (benefit) 7,183 (331) 6,852 32,619 (773) 31,846 Net income (loss) 36,481 (1,246) 35,235 127,734 (2,908) 124,826 Net income (loss) per share: Basic 0.22 (0.01) 0.21 0.79 (0.02) 0.77 Diluted 0.22 (0.01) 0.21 0.77 (0.02) 0.75 Comprehensive income (loss) $ 38,291 $ (1,246) $ 37,045 $ 129,403 $ (2,908) $ 126,495 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Three Months Ended March 31, 2021 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-December 31, 2020 $ 88,461 $ 634,135 Net Income 36,481 36,481 BALANCES-March 31, 2021 124,942 670,515 Adjustments BALANCES-December 31, 2020 (3,165) (3,165) Net Loss (1,246) (1,246) BALANCES-March 31, 2021 (4,411) (4,411) As Corrected BALANCES-December 31, 2020 85,296 630,970 Net Income 35,235 35,235 BALANCES-March 31, 2021 $ 120,531 $ 666,104 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Nine Months Ended March 31, 2021 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-June 30, 2020 $ (2,792) $ 545,689 Net Income 127,734 127,734 BALANCES-March 31, 2021 124,942 670,515 Adjustments BALANCES-June 30, 2020 (1,503) (1,503) Net Loss (2,908) (2,908) BALANCES-March 31, 2021 (4,411) (4,411) As Corrected BALANCES-June 30, 2020 (4,295) 544,186 Net Income 124,826 124,826 BALANCES-March 31, 2021 $ 120,531 $ 666,104 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited) Nine Months Ended March 31, 2021 (in thousands) As Previously Reported Adjustment As Corrected Net income (loss) $ 127,734 $ (2,908) $ 124,826 Deferred income taxes 32,475 (773) 31,702 Accounts receivable (52,905) 3,681 (49,224) Net cash used in operating activities $ (60,947) $ — $ (60,947)

Acquisitions

Acquisitions	9 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONS In accordance with ASC Topic 805, Business Combinations , the Company allocates the purchase price of its acquisitions to the tangible assets, liabilities, and intangible assets acquired based on fair values. Any excess purchase price over those fair values is recorded as goodwill. The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability Lead distribution company —On February 1, 2021, the Company acquired substantially all of the assets of a lead distribution company for an aggregate purchase price of up to $33.5 million (subject to customary adjustments), as set forth in the Asset Purchase Agreement, dated February 1, 2021 (the “Asset Purchase Agreement”). The purchase price is comprised of $30.0 million, of which $24.0 million was paid in cash at the closing of the transaction, with an additional $6.0 million of holdback for indemnification claims, net working capital adjustments, and underperformance. Additionally, the purchase price includes an earnout of up to $3.5 million. The primary purpose of the acquisition was to secure and incorporate the exclusive publisher relationships into the lead generation business of InsideResponse. The Company recorded $0.4 million of acquisition-related costs in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income. During calendar year 2021, the lead distribution company did not achieve the minimum earnout target as set forth in the Asset Purchase Agreement. However, the remaining holdback was earned in full, as the lead distribution company did not fall below the underperformance thresholds as set forth in the Asset Purchase Agreement. The Company settled the remaining holdback of $5.5 million, with interest, after the net working capital true-up of $0.5 million, during the three months ended March 31, 2022. Under the terms of the Asset Purchase Agreement, the total consideration for the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 30,000 Net working capital true-up (499) Total Purchase Consideration $ 29,501 At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The non-compete agreements were valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the benefits of leveraging the exclusive publisher relationships in the business. This acquired goodwill is allocated to Senior (which is also the reporting unit), and $1.6 million will be deductible for tax purposes after adding back acquisition costs and having settled the remaining holdback. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Accounts receivable $ 1,301 Total tangible assets acquired 1,301 Non-compete agreements 5 years 1,000 Vendor relationships 9 years 23,700 Goodwill Indefinite 3,500 Total intangible assets acquired 28,200 Net Assets Acquired $ 29,501 The Company will amortize the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from five Express Med Pharmaceuticals —On April 30, 2021, the Company acquired 100% of the outstanding shares of Express Med Pharmaceuticals, Inc., now SelectRx, a closed-door, long term care pharmacy provider, for an aggregate purchase price of up to $24.0 million (subject to customary adjustments), as set forth in the Stock Purchase Agreement dated April 30, 2021 (the “Stock Purchase Agreement”). The aggregate purchase price of up to $24.0 million is comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any. The primary purpose of the acquisition was to take advantage of the Company's technology and customer base to facilitate better patient care through coordination of strategic, value-based care partnerships. The Company recorded $0.3 million of acquisition-related costs in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income. In addition, as a result of the acquisition, the Company has entered into an operating lease with the former President and Chief Executive Officer of Express Med Pharmaceuticals, now our Executive Vice President of SelectRx. Refer to Note 6 in the condensed consolidated financial statements for further details. The earnout of up to $4.0 million is comprised of two separate provisions. The first provision provides for an earnout of up to $3.0 million and is contingent upon achievement of the following within the first 20 months following the acquisition: facility updates that would allow for processing a minimum of 75,000 active patients, the issuance of pharmacy licenses in all 50 states, and active patients of 15,000 or more. The second provision provides for an earnout of up to $1.0 million and is contingent upon achievement of the following within 36 months following the acquisition: construction of a new facility to accommodate the servicing of additional active patients or 75,000 or more active patients as of the last day of any month prior to the end of the second earnout provision period or as of the end of the second earnout provision period. As the earnout payment is contingent upon continued employment of certain individuals, the Company will recognize the earnout as compensation expense in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income in the period in which it is earned. As of March 31, 2022, the Company has not accrued an earnout payment based on performance to date. The $2.5 million of holdback will be due upon the 15-month anniversary of the closing date of the acquisition. Under the terms of the Stock Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 20,000 Net working capital true-up (483) Closing cash 20 Total purchase consideration $ 19,537 At the date of acquisition, the fair value of net tangible assets acquired, excluding property and equipment, approximated their carrying value. The property and equipment was valued primarily using the cost and sales comparison approach to value. For the proprietary software acquired, the replacement cost method under the cost approach was used, estimating the cost to rebuild the software. The non-compete agreement was valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the SelectRx business with the Company's technology and existing customer base. This acquired goodwill is allocated to Senior (which is also the reporting unit), and the Company expects approximately $16.3 million to be deductible for tax purposes after adding back acquisition costs and excluding the holdback not yet paid. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 20 Accounts receivable 613 Other current assets 28 Property and equipment, net 287 Accounts payable (280) Accrued expenses, including compensation and benefits (45) Net tangible assets acquired 623 Proprietary Software 3 years 550 Non-compete agreements 5 years 100 Customer relationships 1 year 200 Goodwill Indefinite 18,064 Total intangible assets acquired 18,914 Net assets acquired $ 19,537 The Company will amortize the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from one Simple Meds —On August 31, 2021, SelectRx acquired 100% of the outstanding equity interests of Simple Meds, a full-service pharmaceutical distributor, for an aggregate purchase price of $7.0 million (subject to customary adjustments), as set forth in the Membership Interest Purchase Agreement dated August 31, 2021. The aggregate purchase price of $7.0 million was paid in cash at the closing of the transaction. The primary purpose of the acquisition was to accelerate the expansion of the prescription drug management business by combining the operations and existing infrastructure of Simple Meds into SelectRx. Under the terms of the Membership Interest Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 7,000 Net working capital true-up 347 Closing cash 61 Total purchase consideration $ 7,408 At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The customer relationships were valued using the multiple period excess earnings method, and as such, were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the Simple Meds business with the Company's technology and existing customer base. This acquired goodwill is allocated to Senior (which is also the reporting unit), and the Company expects approximately $5.6 million to be deductible for tax purposes after adding back acquisition costs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 61 Accounts receivable 634 Other current assets 474 Property and equipment, net 415 Accounts payable (259) Net tangible assets acquired 1,325 Customer relationships 1 year 370 Goodwill Indefinite 5,713 Total intangible assets acquired 6,083 Net assets acquired $ 7,408 From the date of acquisition, August 31, 2021, through March 31, 2022, Simple Meds generated $8.6 million of pharmacy prescription revenue.

Property And Equipment_Net

Property And Equipment—Net	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property And Equipment—Net	PROPERTY AND EQUIPMENT—NET Property and equipment—net consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Computer hardware $ 25,405 $ 13,351 Machinery and equipment (1) 8,883 2,667 Leasehold improvements 19,276 18,525 Furniture and fixtures 4,623 5,004 Work in progress 11,200 7,220 Total 69,387 46,767 Less accumulated depreciation (23,829) (17,257) Property and equipment—net $ 45,558 $ 29,510 (1) Includes financing lease right-of-use assets. Work in progress as of March 31, 2022 primarily represents computer equipment and machinery not yet put into service and not yet being depreciated. Work in progress as of June 30, 2021, primarily represents computer equipment and machinery not yet put into service and not yet being depreciated. Depreciation expense for the three months ended March 31, 2022 and 2021, was $3.3 million and $2.0 million, respectively, and $8.4 million and $5.6 million for the nine months ended March 31, 2022 and 2021, respectively.

Software_Net

Software—Net	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Software—Net	SOFTWARE—NET Software—net consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Software $ 24,147 $ 16,530 Work in progress 3,658 3,826 Total 27,805 20,356 Less accumulated amortization (12,247) (7,745) Software—net $ 15,558 $ 12,611 Work in progress as of March 31, 2022 and June 30, 2021, represents costs incurred for software not yet put into service and are not yet being amortized. For each of the three months ended March 31, 2022 and 2021, the Company capitalized internal-use software and website development costs of $2.2 million and recorded amortization expense of $1.6 million and $1.0 million, respectively. For the nine months ended March 31, 2022 and 2021, the Company capitalized internal-use software and website development costs of $6.6 million and $5.4 million, respectively, and recorded amortization expense of $4.5 million and $2.7 million, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets — The Company's intangible assets include those acquired as part of the acquisitions listed in the table below (refer to Note 2 to the condensed consolidated financial statements for further details). The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Based on the Company’s third quarter analysis, no impairment was recorded on the Company’s long-lived assets. Goodwill— The Company recorded as goodwill the excess of the purchase price over the estimated fair values of identifiable assets and liabilities acquired as part of the acquisitions listed in the table below (refer to Note 2 to the condensed consolidated financial statements for further details). The Company performs its annual goodwill impairment assessment as of April 1, or more frequently if it believes that indicators of impairment exist. During each of the three and nine months ended March 31, 2022 and 2021, there were no such indicators. Goodwill is assigned to reporting units that are expected to benefit from the synergies of the business combination as of the acquisition date and becomes identified with that reporting unit in its entirety. As such, the reporting unit as a whole supports the recovery of its goodwill. For the following acquisitions, the reporting units to which goodwill has been assigned and the associated reportable segments are as follows: Acquisition Reporting Unit Reportable Segment Auto & Home-controlling interest Auto & Home Auto & Home InsideResponse Senior Senior Lead distribution company Senior Senior Express Med Pharmaceuticals Senior Senior Simple Meds Senior Senior The carrying amounts, accumulated amortization, net carrying value, and weighted average remaining life of our definite-lived amortizable intangible assets as well as our goodwill are presented in the tables below (dollars in thousands, useful life in years): March 31, 2022 June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Total intangible assets subject to amortization Customer relationships $ 17,492 $ (5,542) $ 11,950 $ 17,122 $ (3,448) $ 13,674 Trade name 2,680 (1,027) 1,653 2,680 (625) 2,055 Proprietary software 1,592 (719) 873 1,592 (382) 1,210 Non-compete agreements 1,292 (374) 918 1,292 (163) 1,129 Vendor relationships 23,700 (3,072) 20,628 23,700 (1,098) 22,602 Total intangible assets $ 46,756 $ (10,734) $ 36,022 6.4 $ 46,386 $ (5,716) $ 40,670 7.1 Total indefinite-lived assets Goodwill-Auto & Home $ 5,364 $ 5,364 Goodwill-Senior 68,368 62,655 Total goodwill $ 73,732 $ 68,019 For the three months ended March 31, 2022 and 2021, amortization expense related to intangible assets totaled $1.7 million and $1.3 million, respectively, and $5.0 million and $2.9 million for the nine months ended March 31, 2022 and 2021, respectively. Changes in the balance of goodwill for the nine months ended March 31, 2022, are as follows (in thousands): Balance, June 30, 2021 $ 68,019 Goodwill from the acquisition of Simple Meds 5,713 Balance, March 31, 2022 $ 73,732 As of March 31, 2022, expected amortization expense in future fiscal periods is as follows (in thousands): Trade Name Proprietary Software Non-compete agreements Vendor Relationships Customer relationships Total Remainder fiscal 2022 $ 134 $ 96 $ 71 $ 660 $ 690 $ 1,651 2023 536 339 273 2,633 2,385 6,166 2024 536 308 220 2,633 2,319 6,016 2025 447 130 220 2,633 2,316 5,746 2026 — — 134 2,633 2,313 5,080 Thereafter — — — 9,436 1,927 11,363 Total $ 1,653 $ 873 $ 918 $ 20,628 $ 11,950 $ 36,022

Leases

Leases	9 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	LEASES The majority of the Company’s leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term. The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Jacksonville, Florida; Overland Park, Kansas; Des Moines, Iowa; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise). The Company's operating leases have remaining lease terms of less than one year up to fourteen years. On February 7, 2022 and April 6, 2022, the Company executed noncancelable subleases for a portion of its office facilities in Overland Park, Kansas. The former commenced March 23, 2022, while the latter commences September 2, 2022. These subleases run through the remaining term of their primary leases, which terminate July 31, 2029, and are expected to generate $11.9 million in sublease income, which will be recorded as a reduction of lease expense in the condensed consolidated statement of comprehensive income. The Company may consider entering into additional sublease arrangements in the future. In addition, during the three months ended March 31, 2022, the Company exercised an early termination option for the Des Moines, Iowa office lease, with a new termination date of September 30, 2022, resulting in an early termination penalty of $0.3 million, which was recorded as part of the remeasurement of the operating lease liability and will result in accelerated amortization of the right-of-use asset over the shortened remaining term of the lease. Lease Costs —The components of lease costs were as follows periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Finance lease costs (1) $ 48 $ 69 $ 132 $ 194 Operating lease costs (2) 1,998 1,980 6,056 5,859 Short-term lease costs 40 42 69 168 Variable lease costs (3) 227 201 696 915 Sublease income (23) (403) (488) (638) Total net lease costs $ 2,290 $ 1,889 $ 6,465 $ 6,498 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. Maturities of Lease Liabilities —As of March 31, 2022, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 2,212 57 2,269 2023 8,710 147 8,857 2024 9,032 38 9,070 2025 9,203 38 9,241 2026 7,040 38 7,078 2027 5,666 32 5,698 Thereafter 12,885 — 12,885 Total undiscounted lease payments 54,748 350 55,098 Less: interest 14,266 30 14,296 Present value of lease liabilities $ 40,482 $ 320 $ 40,802 As of March 31, 2022, the Company had $3.5 million of undiscounted future payments for operating leases expected to commence between the fourth quarter of fiscal 2022 and the first quarter of fiscal 2023, with lease terms ranging from seven
Leases	LEASES The majority of the Company’s leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term. The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Jacksonville, Florida; Overland Park, Kansas; Des Moines, Iowa; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise). The Company's operating leases have remaining lease terms of less than one year up to fourteen years. On February 7, 2022 and April 6, 2022, the Company executed noncancelable subleases for a portion of its office facilities in Overland Park, Kansas. The former commenced March 23, 2022, while the latter commences September 2, 2022. These subleases run through the remaining term of their primary leases, which terminate July 31, 2029, and are expected to generate $11.9 million in sublease income, which will be recorded as a reduction of lease expense in the condensed consolidated statement of comprehensive income. The Company may consider entering into additional sublease arrangements in the future. In addition, during the three months ended March 31, 2022, the Company exercised an early termination option for the Des Moines, Iowa office lease, with a new termination date of September 30, 2022, resulting in an early termination penalty of $0.3 million, which was recorded as part of the remeasurement of the operating lease liability and will result in accelerated amortization of the right-of-use asset over the shortened remaining term of the lease. Lease Costs —The components of lease costs were as follows periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Finance lease costs (1) $ 48 $ 69 $ 132 $ 194 Operating lease costs (2) 1,998 1,980 6,056 5,859 Short-term lease costs 40 42 69 168 Variable lease costs (3) 227 201 696 915 Sublease income (23) (403) (488) (638) Total net lease costs $ 2,290 $ 1,889 $ 6,465 $ 6,498 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. Maturities of Lease Liabilities —As of March 31, 2022, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 2,212 57 2,269 2023 8,710 147 8,857 2024 9,032 38 9,070 2025 9,203 38 9,241 2026 7,040 38 7,078 2027 5,666 32 5,698 Thereafter 12,885 — 12,885 Total undiscounted lease payments 54,748 350 55,098 Less: interest 14,266 30 14,296 Present value of lease liabilities $ 40,482 $ 320 $ 40,802 As of March 31, 2022, the Company had $3.5 million of undiscounted future payments for operating leases expected to commence between the fourth quarter of fiscal 2022 and the first quarter of fiscal 2023, with lease terms ranging from seven

Debt

Debt	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	DEBT Debt consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Term Loans $ 470,732 $ 471,912 DDTL Facility 244,388 — Unamortized debt issuance costs (3,163) (4,081) Unamortized debt discount (5,402) (6,428) Total debt 706,555 461,403 Less current portion of long-term debt: (7,169) (2,360) Long-term debt $ 699,386 $ 459,043 On November 5, 2019, the Company entered into a credit agreement with UMB Bank N.A. (“UMB”) as a lender and revolving agent and Morgan Stanley Capital Administrators, Inc. as a lender and the administrative agent for a syndicate of lenders party to the agreement (replaced by Wilmington Trust as administrative agent effective February 24, 2022). On February 24, 2021, November 2, 2021, and December 23, 2021, the Company entered into amendments to the credit agreement ( individually, the “First Amendment”, “Second Amendment”, and “Third Amendment” , together with the original credit agreement and any subsequent amendments, the “Senior Secured Credit Facility” ) with certain of its existing lenders and new lenders. The First Amendment provided for an additional $231.0 million in term loans (together with the initial $425.0 million, the “Term Loans”) and added a $145.0 million se nior secured delayed draw term loan facility (the "DDTL Facility") . The Second Amendment provided for additional commitments of $25.0 million, in addition to the initial $75.0 million, for the s ecured revolving loan facility (the “Revolving Credit Facility”) and an additional $200.0 million under the DDTL Facility. The Third Amendment provided for additional commitments of $35.0 million under the Revolving Credit Facility. After giving effect to the amendments, in aggregate, the Senior Secured Credit Facility provides for (1) an aggregate principal amount of up to $135.0 million under the Revolving Credit Facility (2) Term Loans in an aggregate principal amount of $656.0 million, of which $470.7 million is outstanding as of March 31, 2022, and (3) a $345.0 million DDTL Facility, of which $244.4 million is outstanding as of March 31, 2022. As of May 5, 2022, the available borrowing capacities under the Revolving Credit Facility and DDTL Facility were $135.0 million and $100.0 million, respectively. In accordance with ASC 470-50-40 “ Debt Modification and Extinguishments ”, the Second and Third Amendments were accounted for as debt modifications, and the $3.0 million original issue discount paid to the two lenders of the DDTL Facility was capitalized and is being amortized on a straight-line basis over the remaining life of the agreement through interest expense. Additionally, the Company paid $1.2 million in costs as part of the transaction that were included in general and administrative expense in the condensed consolidated statements of comprehensive income. As a result of the Third Amendment, the Company incurred $0.3 million of costs related to the new commitments, which costs were capitalized and are being amortized on a straight-line basis over the remaining life of the agreement through interest expense. The Revolving Credit Facility accrues interest on amounts drawn at a rate per annum equal to either (a) LIBOR plus 4.0% or (b) a base rate plus 3.0%, at the Company’s option, and the Company pays an unused commitment fee of 0.15% in respect of the unutilized commitments under the Revolving Credit Facility. The Term Loans and the DDTL Facility bear interest on the outstanding principal amounts thereof at a rate per annum equal to either (a) LIBOR (subject to a floor of 0.75%) plus 5.00% or (b) a base rate plus 4.00%, at the Company’s option, and the Company pays a ticking fee based on the average daily balance of the unused amount of the aggregate DDTL Facility commitments during the preceding fiscal quarter, multiplied by 1% per annum. The Senior Secured Credit Facility has a maturity date of November 5, 2024, with the Term Loans becoming mandatorily repayable as of March 31, 2022, in equal quarterly installments in an aggregate annual amount equal to 1% of the original principal amount of the Term Loans, with the remaining balance payable on the maturity date. The DDTL Facility also became mandatorily repayable beginning March 31, 2022, in equal quarterly installments equal to 0.25% of all DDTL Facility loans that have been outstanding for a full fiscal quarter prior to each such repayment date, with the remaining balance payable on the maturity date. As of March 31, 2022, the Company has made principal payments of $1.2 million and $0.6 million on the Term Loans and DDTL Facility, respectively. The remaining $100.0 million of the DDTL Facility may be drawn from time to time, subject to certain conditions, until January 15, 2023. The Senior Secured Credit Facility contains customary affirmative and negative covenants and events of default and a financial covenant requiring the Company and certain of its subsidiaries to maintain a minimum asset coverage ratio. As of March 31, 2022, the Company was in compliance with all of the required covenants. The obligations of the Company are guaranteed by certain of the Company’s subsidiaries and secured by a security interest in all assets of the Company, subject to certain exceptions. The Company has incurred a total of $27.1 million in debt issuance costs and debt discounts related to the Senior Secured Credit Facility, of which $22.9 million was capitalized and is being amortized on a straight-line basis over the remaining life of the Senior Secured Credit Facility. Total amortization was $1.2 million and $0.8 million for the three months ended March 31, 2022 and 2021, respectively, and $4.2 million and $2.5 million for the nine months ended March 31, 2022 and 2021, respectively, which was included in interest expense, net in the Company’s condensed consolidated statements of comprehensive income. The Company uses derivative financial instruments to hedge against its exposure to fluctuations in interest rates associated with the Term Loans. As of March 31, 2022, the Company had an outstanding receive-variable, pay-fixed interest rate swap on the notional amount of $325.0 million of the Company’s total outstanding Term Loans balance with a fixed rate of 5.00% plus 1.03% (the “Amended Interest Rate Swap”), which terminates on November 5, 2024. As of March 31, 2022, the Amended Interest Rate Swap had a fair value of $12.3 million and was recorded in other assets in the condensed consolidated balance sheet. The Company classifies its Amended Interest Rate Swap as a Level 2 on the fair value hierarchy as the majority of the inputs used to value it primarily includes other than

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Lease Obligations —Refer to Note 6 to the condensed consolidated financial statements for commitments related to our operating leases. Legal Contingencies and Obligations —From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. Such matters may include insurance regulatory claims; commercial, tax, employment, or intellectual property disputes; matters relating to competition and sales practices; and claims for damages arising out of the use of the Company’s services. The Company may also become subject to lawsuits related to past or future acquisitions, divestitures, or other transactions, including matters related to representations and warranties, indemnities, and assumed or retained liabilities. The Company is not currently aware of any legal proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, operating results, or cash flows; however, in the event of unexpected developments, it is possible that the ultimate resolution of certain ongoing matters, if unfavorable, could be materially adverse to our business, prospects, financial condition, liquidity, results of operation, cash flows, or capital levels. Securities Class Actions As previously disclosed, the Company and certain of its executive officers and current and former directors have been named as defendants in two putative securities class actions lawsuits filed in the U.S. District Court for the Southern District of New York on August 17 and October 7, 2021, respectively. There have been no material developments in either of these matters since their disclosure in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2021. Stockholder Derivative Suit On March 25, 2022, a stockholder derivative action was filed in the U.S. District Court for the District of Delaware by an alleged stockholder of the Company, purportedly on the Company’s behalf. The lawsuit was brought against certain of the Company’s current and former directors and officers (together, the “Defendants”), and against the Company, as nominal defendant. The complaint, captioned Jadlow v. Danker, et al., Case No. 1:22-cv-00391-RGA, alleges that certain of the Defendants violated Section 14(a) of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s business, operations, and prospects. The complaint also asserts claims against all Defendants for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets based on the same general underlying conduct. The complaint also seeks contribution under Sections 10(b) and 21D of the Exchange Act and Section 11(f) of the Securities Act from the individual defendants named in the Securities Class Actions. The complaint seeks unspecified damages for the Company, restitution, reformation and improvement of its corporate governance and internal procedures regarding compliance with laws, and reimbursement of costs and attorneys’ fees. The Company does not currently believe this matter will have a material adverse effect on our results of operations, financial condition, or liquidity; however, this matter could be costly to defend and could divert the attention of management and other resources from operations.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Shareholders' Equity	SHAREHOLDERS' EQUITY Common Stock —As of March 31, 2022, the Company has reserved the following authorized, but unissued, shares of common stock: Employee Stock Purchase Plan 877,092 Stock awards outstanding under 2020 Plan 4,752,141 Stock awards available for grant under 2020 Plan 9,571,645 Options outstanding under 2003 Plan 1,701,424 Total 16,902,302 Share-Based Compensation Plans The Company has awards outstanding from two share-based compensation plans: the 2003 Stock Incentive Plan (the “2003 Stock Plan”) and the 2020 Omnibus Incentive Plan (the “2020 Stock Plan” and, collectively with the 2003 Stock Plan, the “Stock Plans”). However, no further awards will be made under the 2003 Stock Plan. The 2020 Stock Plan provides for the grant of incentive stock options (“ISO's”), nonstatutory stock options (“NSO's”), stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU's”), performance-based restricted stock units (“PSU's”), and other forms of equity compensation (collectively, “stock awards”). All awards (other than ISOs, which may be granted only to current employees of the Company) may be granted to employees, non-employee directors, and consultants of the Company and its subsidiaries and affiliates. The number of shares of common stock available for issuance as of March 31, 2022, pursuant to future awards under the Company's 2020 Stock Plan is 9,571,645. The number of shares of the Company's common stock reserved under the 2020 Stock Plan is subject to an annual increase on the first day of each fiscal year, beginning on July 1, 2021, equal to 3% of the total outstanding shares of common stock as of the last day of the immediately preceding fiscal year. The maximum number of shares of common stock that may be issued upon the exercise of ISO's will be 4,000,000. The shares of common stock covered by any award (including any award granted pursuant to the 2003 Stock Plan) that is forfeited, terminated, expired, or lapsed without being exercised or settled for cash will again become available for issuance under the 2020 Stock Plan. With respect to any award, if the exercise price and/or tax withholding obligations are satisfied by delivering shares to the Company (by actual delivery or attestation), or if the exercise price and/or tax withholding obligations are satisfied by withholding shares otherwise issuable pursuant to the award, the share reserve shall nonetheless be reduced by the gross number of shares subject to the award. The Company accounts for its share-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation (“ASC 718”) which requires all share-based compensation to be recognized in the income statement based on fair value and applies to all awards granted, modified, canceled, or repurchased after the effective date. Total share-based compensation for stock awards included in general and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Share-based compensation related to: Equity classified stock options $ 805 $ 451 $ 2,429 $ 1,269 Equity classified RSU's 993 648 3,073 1,608 Equity classified PSU's 231 190 318 512 Total $ 2,029 $ 1,289 $ 5,820 $ 3,389 Stock Options — The stock options outstanding under the 2003 Stock Plan vest as to one-third after the vesting commencement date and as to 1/24 of the remaining shares subject to the stock option monthly thereafter, subject to the award recipient’s continued employment through the applicable vesting date. Upon a termination of employment for any reason other than for “Cause” (as defined in the 2003 Stock Plan), any unvested and outstanding stock options would generally be forfeited for no consideration, and any vested and outstanding stock options would remain exercisable for 90 days following the date of termination (and, in the case of a termination of employment due to death or disability, for 12 months following the date of termination). Stock options expire 10 years from the date of grant. The terms for ISO's and NSO's awarded in the 2020 Stock Plan are the same as in the 2003 Stock Plan with the exception that the options generally shall vest and become exercisable in four equal installments on each of the first four anniversaries of the grant date, subject to the award recipient’s continued employment through the applicable vesting date. Stock options are granted with an exercise price that is no less than 100% of the fair market value of the underlying shares on the date of the grant. The fair value of each option (for purposes of calculation of share-based compensation expense) is estimated using the Black-Scholes-Merton option pricing model that uses assumptions determined as of the date of the grant. Use of this option pricing model requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of the Company's common stock price over the expected term (“volatility”), the number of options that will ultimately not complete their vesting requirements (“assumed forfeitures”), the risk-free interest rate that reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a remaining life similar to the expected term (“risk-free interest rate”), and the dividend yield assumption which is based on the Company's dividend payment history and management's expectations of future dividend payments (“dividend yield”). Changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the condensed consolidated statements of comprehensive income. The Company used the following weighted-average assumptions for the stock options granted during the periods presented below: Nine Months Ended March 31, 2022 2021 Volatility 36.0% 25.0% Risk-free interest rate 1.4% 0.4% Dividend yield —% —% Assumed forfeitures —% —% Expected term (in years) 6.25 6.24 Weighted-average fair value (per share) $3.36 $4.89 The following table summarizes stock option activity under the Stock Plans for the nine months ended March 31, 2022: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Outstanding—June 30, 2021 3,398,513 $ 8.60 Options granted 2,460,675 10.23 Options exercised (350,222) 3.74 Options forfeited/expired/cancelled (122,994) 17.81 Outstanding—March 31, 2022 5,385,972 $ 9.45 7.27 $ 3,449 Vested and exercisable—March 31, 2022 2,005,527 $ 3.93 3.94 $ 3,140 As of March 31, 2022, there was $10.3 million in unrecognized compensation cost related to unvested stock options granted, which is expected to be recognized over a weighted-average period of 3.01 years. The Company received cash of $0.9 million and $1.4 million in connection with stock options exercised during the three months ended March 31, 2022 and 2021, respectively, and $3.2 million and $1.8 million in connection with stock options exercised, net of cashless exercises, during the nine months ended March 31, 2022 and 2021, respectively. Restricted Stock — The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the nine months ended March 31, 2022: Number of Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 356,285 $ 19.12 Granted 505,729 15.42 Vested (84,348) 19.72 Forfeited (37,324) 17.86 Unvested as of March 31, 2022 740,342 $ 16.59 As of March 31, 2022, there was $9.5 million of unrecognized compensation cost related to unvested restricted stock units granted, which is expected to be recognized over a weighted-average period of 2.75 years. Performance Stock — The following table summarizes performance stock unit activity under the 2020 Stock Plan for the nine months ended March 31, 2022: Number of Performance Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 (1) 132,921 $ 17.97 Granted (1) 196,080 17.80 Vested — — Forfeited (1,750) 17.89 Performance adjustment (2) (163,626) Unvested as of March 31, 2022 163,625 $ 17.87 (1) Reflects PSU’s at 100% achievement of predefined financial performance targets. If performance metrics are met, PSU’s will vest, at the end of a three-year performance period. The number of shares that could be earned for the fiscal year 2021 tranche will range from 0% to 150% of the target, and the number of shares that could be earned for the fiscal year 2022 tranche will range from 0% to 200% of the target. (2) Represents adjustments to previously granted PSU’s to reflect changes in estimates of future financial performance against targets. As of March 31, 2022, there was $1.9 million of unrecognized compensation cost related to unvested performance stock units granted, which is expected to be recognized over a weighted-average period of 2.07 years. ESPP — The purpose of the Company’s employee stock purchase plan (“ESPP”) is to provide eligible employees an opportunity to purchase shares of the Company’s common stock at a discounted price through accumulated payroll deductions. Pursuant to the terms of the ESPP, which was amended and restated effective as of April 1, 2022, participants may purchase shares on the exercise date at a price equal to 85% of the fair market value of the Company’s common stock as of either the exercise date or the first day of the relevant offering period, whichever is lesser. During the nine months ended March 31, 2022, the Company issued 466,468 shares to its

Revenues from Contracts with Cu

Revenues from Contracts with Customers	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	REVENUES FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue from Contracts with Customers —The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Senior: Commission revenue: Medicare advantage $ 176,603 $ 181,040 $ 355,949 $ 493,745 Medicare supplement 912 2,981 4,849 23,716 Prescription drug plan 393 449 1,393 2,166 Dental, vision, and health 4,150 4,671 12,285 13,041 Other commission revenue 1,415 619 4,269 1,822 Total commission revenue 183,473 189,760 378,745 534,490 Production bonus and other revenue 49,699 25,840 118,714 69,819 Total Senior revenue 233,172 215,600 497,459 604,309 Life: Commission revenue: Term 15,779 19,777 48,151 59,549 Final expense 19,626 20,088 55,100 46,362 Total commission revenue 35,405 39,865 103,251 105,911 Production bonus and other revenue 3,995 4,958 16,361 16,006 Total Life revenue 39,400 44,823 119,612 121,917 Auto & Home: Total commission revenue 6,539 5,910 19,187 21,014 Production bonus and other revenue 613 1,063 1,568 2,738 Total Auto & Home revenue 7,152 6,973 20,755 23,752 Eliminations: Total commission revenue (2,879) (319) (5,689) (784) Production bonus and other revenue (1,732) (1,731) (4,516) (3,509) Total Elimination revenue (4,611) (2,050) (10,205) (4,293) Total commission revenue 222,538 235,216 495,494 660,631 Total production bonus and other revenue 52,575 30,130 132,127 85,054 Total revenue $ 275,113 $ 265,346 $ 627,621 $ 745,685 Contract Balances —After a policy is sold, the Company has no material additional or recurring obligations to the policyholder or the insurance carrier. As such, there are no contract liabilities recorded in the condensed consolidated balance sheets. During the nine months ended March 31, 2021, there was no activity in the contract asset balances other than the movement over time between long-term and short-term commissions receivable and accounts receivable as the policy is renewed, as shown on the balance sheet. A roll forward of commissions receivable (current and long term) is shown below for the nine months ended March 31, 2022: (in thousands) Balance as of June 30, 2021 $ 845,897 Commission revenue from revenue recognized 318,399 Net commission revenue adjustment from change in estimate (157,368) Amounts recognized as accounts receivable (168,632) Balance as of March 31, 2022 $ 838,296 The $157.4 million adjustment from change in estimate includes adjustments from the Company’s reassessment of each of its cohorts’ transaction prices. $145.0 million of the total adjustment was due to the increase in actual lapse rates for Senior MA policies during calendar year 2021 and overall lower persistency from early data received for the January 2022 renewals and was recorded during the three months ended December 31, 2021. Approximately 62%, 28%, and 8% of the adjustment from the change in estimate were from approved policies sold in fiscal years 2021, 2020, and 2019, respectively. In addition, there was a $6.1 million adjustment during the three months ended March 31, 2022, for renewal year lapses for calendar year 2022 for Senior MA policies. Production Bonuses and Other —During the nine months ended March 31, 2022, the Company received advance payments of marketing development funds, which are amortized over the course of the appropriate fiscal year based on policies sold. As of March 31, 2022, there was an unamortized balance remaining of $0.4 million of fiscal year 2022 and 2023 marketing development funds recorded in other current liabilities in the condensed consolidated balance sheet.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES For the three months ended March 31, 2022 and 2021, we recognized income tax benefit of $2.6 million and income tax expense of $6.9 million, respectively, representing effective tax rates of 29.1% and 16.3%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the three months ended March 31, 2022, were primarily related to state income taxes. The differences from our federal statutory tax rate to the effective tax rate for the three months ended March 31, 2021, were primarily related to state income taxes, partially offset by state tax credits such as the Kansas High Performance Incentive Program (“HPIP”) and discrete items for the period related to the exercise of non-qualified stock options. For the nine months ended March 31, 2022 and 2021, we recognized income tax benefit of $65.2 million and income tax expense of $31.8 million, respectively, representing effective tax rates of 25.5% and 20.3%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the nine months ended March 31, 2022, were primarily related to state income taxes. The differences from our federal statutory tax rate to the effective tax rate for the nine months ended March 31, 2021, were primarily related to state income taxes, partially offset by state tax credits such as HPIP and discrete items for the period related to the exercise of non-qualified stock options. Assessing the realizability of the Company’s deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. The Company forecasts taxable income by considering all available positive and negative evidence, including historical data and future plans and estimates. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. The Company continues to recognize its deferred tax assets as of March 31, 2022, as it believes it is more likely than not that the net deferred tax assets will be realized. The Company recognizes a significant deferred tax liability due to the difference in the timing of revenue recognition for financial statement and tax purposes. For financial statement

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NET INCOME (LOSS) PER SHARE The Company calculates net income (loss) per share as defined by ASC Topic 260, “ Earnings per Share” . Basic net income (loss) per share (“Basic EPS”) is computed by dividing net income (loss) attributable to common shareholders by the weighted-average common stock outstanding during the respective period. Diluted net income (loss) per share (“Diluted EPS”) is computed by dividing net income (loss) attributable to common and common equivalent shareholders by the total of the weighted-average common stock outstanding and common equivalent shares outstanding during the respective period. For the purpose of calculating the Company’s Diluted EPS, common equivalent shares outstanding include common shares issuable upon the exercise of outstanding employee stock options, unvested RSU's, PSU’s assuming the performance conditions are satisfied as of the end of the reporting period, and common shares issuable upon the conclusion of each ESPP offering period. The number of common equivalent shares outstanding has been determined in accordance with the treasury stock method for employee stock options, RSU's, PSU’s, and common stock issuable pursuant to the ESPP to the extent they are dilutive. Under the treasury stock method, the exercise price paid by the option holder and future share-based compensation expense that the Company has not yet recognized are assumed to be used to repurchase shares. The following table sets forth the computation of net income (loss) per share for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands, except per share amounts) 2022 2021 2022 2021 Basic: Numerator: Net income (loss) attributable to common shareholders $ (6,448) $ 35,235 $ (190,609) $ 124,826 Denominator: Weighted-average common stock outstanding 164,083 163,023 163,914 162,705 Net income (loss) per share—basic: $ (0.04) $ 0.21 $ (1.16) $ 0.77 Diluted: Numerator: Net income (loss) attributable to common and common equivalent shareholders $ (6,448) $ 35,235 $ (190,609) $ 124,826 Denominator: Weighted-average common stock outstanding 164,083 163,023 163,914 162,705 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP (1) — 2,708 — 2,790 Total common and common equivalent shares outstanding 164,083 165,731 163,914 165,495 Net income (loss) per share—diluted: $ (0.04) $ 0.21 $ (1.16) $ 0.75 (1) Excluded from the computation of net income (loss) per share-diluted for the three and nine months ended March 31, 2022, because the effect would have been anti-dilutive. The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted for the periods presented because including them would have been anti-dilutive are as follows for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP 5,393 322 5,069 918 Shares subject to outstanding PSU's (1) 164 132 219 117 Total 5,557 454 5,288 1,035 (1) The weighted-average number of shares excluded from the computation of net income (loss) per share-diluted because the performance conditions associated with these awards were not met.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company’s reportable segments have been determined in accordance with ASC 280, Segment Reporting (“ASC 280”). The Company currently has three reportable segments: i) Senior, ii) Life, and iii) Auto & Home. Senior primarily sells senior Medicare-related health insurance products and also includes Population Health and InsideResponse. Life primarily sells term life and final expense products, and Auto & Home primarily sells individual automobile and homeowners’ insurance. In addition, the Company accounts for non-operating activity, share-based compensation expense, certain intersegment eliminations, and the costs of providing corporate and other administrative services in its administrative division, Corporate & Eliminations. These services are not directly identifiable with the Company’s reportable segments and are shown in the tables below to reconcile the reportable segments to the condensed consolidated financial statements. The Company has not aggregated any operating segments together to represent a reportable segment. The Company reports segment information based on how its chief operating decision maker (“CODM”) regularly reviews its operating results, allocates resources, and makes decisions regarding business operations. The performance measures of the segments include total revenue and Adjusted EBITDA because management believes that such information is the most relevant in evaluating the results of the respective segments relative to other entities that operate in the same industries. Costs of revenue, marketing and advertising, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, marketing and advertising, technical development, and general and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; restructuring expenses; and non-recurring expenses such as severance payments and transaction costs. Our CODM does not separately evaluate assets by segment; therefore, assets by segment are not presented. The following table presents information about the reportable segments for the three months ended March 31, 2022: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 233,172 $ 39,400 $ 7,152 $ (4,611) $ 275,113 Operating expenses (200,990) (41,288) (6,002) (13,819) (1) (262,099) Other expenses, net — — — (23) (23) Adjusted EBITDA $ 32,182 $ (1,888) $ 1,150 $ (18,453) 12,991 Share-based compensation expense (2,143) Non-recurring expenses (2) (703) Depreciation and amortization (6,679) Loss on disposal of property, equipment, and software, net (384) Interest expense, net (12,179) Income tax benefit 2,649 Net loss $ (6,448) (1) Operating expenses in the Corp & Elims division primarily include $12.0 million in salaries and benefits for certain general, administrative, and IT related departments, and $4.1 million in professional services fees. (2) These expenses primarily consist of costs related to the change in administrative agent with respect to the Senior Secured Credit Facility and severance expenses. The following table presents information about the reportable segments for the three months ended March 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 215,600 $ 44,823 $ 6,973 $ (2,050) $ 265,346 Operating expenses (140,111) (43,225) (5,877) (12,507) (1) (201,720) Other expenses, net — — — (15) (15) Adjusted EBITDA $ 75,489 $ 1,598 $ 1,096 $ (14,572) 63,611 Share-based compensation expense (1,429) Non-recurring expenses (2) (4,667) Fair value adjustments to contingent earnout obligations (334) Depreciation and amortization (4,323) Loss on disposal of property, equipment, and software (101) Interest expense, net (7,355) Loss on extinguishment of debt (3,315) Income tax expense (6,852) Net income $ 35,235 (1) Operating expenses in the Corp & Elims division primarily include $9.8 million in salaries and benefits for certain general, administrative, and IT related departments and $3.2 million in professional services fees. (2) These expenses primarily consist of costs incurred for the First Amendment, the acquisition of a lead distribution company, re-designation of the hedge, and the Secondary Offering. The following table presents information about the reportable segments for the nine months ended March 31, 2022: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 497,459 $ 119,612 $ 20,755 $ (10,205) $ 627,621 Operating expenses (646,883) (117,347) (16,798) (43,149) (1) (824,177) Other expenses, net — — — (177) (177) Adjusted EBITDA $ (149,424) $ 2,265 $ 3,957 $ (53,531) (196,733) Share-based compensation expense (6,252) Non-recurring expenses (2) (2,857) Depreciation and amortization (17,957) Loss on disposal of property, equipment, and software, net (739) Interest expense, net (31,300) Income tax benefit 65,229 Net loss $ (190,609) (1) Operating expenses in the Corp & Elims division primarily include $33.6 million in salaries and benefits for certain general, administrative, and IT related departments, and $13.1 million in professional services fees. (2) These expenses primarily consist of costs incurred for the Second Amendment, costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds, costs related to the change in administrative agent with respect to the Senior Secured Credit Facility, and severance expenses. The following table presents information about the reportable segments for the nine months ended March 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 604,309 $ 121,917 $ 23,752 $ (4,293) $ 745,685 Operating expenses (385,363) (105,532) (16,889) (34,771) (1) (542,555) Other expenses, net — — — (58) (58) Adjusted EBITDA $ 218,946 $ 16,385 $ 6,863 $ (39,122) 203,072 Share-based compensation expense (3,689) Non-recurring expenses (2) (5,490) Fair value adjustments to contingent earnout obligations (1,487) Depreciation and amortization (11,260) Loss on disposal of property, equipment, and software (261) Interest expense, net (20,898) Loss on extinguishment of debt (3,315) Income tax expense (31,846) Net income $ 124,826 (1) Operating expenses in the Corp & Elims division primarily include $24.8 million in salaries and benefits for certain general, administrative, and IT related departments and $9.5 million in professional services fees. (2) These expenses primarily consist of costs incurred for the First Amendment, the acquisition of a lead distribution company, re-designation of the hedge, and the Secondary Offering as well as non-recurring compensation to a former executive, severance expenses, and expenses related to business continuity in response to the COVID-19 pandemic. Revenues from each of the reportable segments are earned from transactions in the United States and follow the same accounting policies used for the Company’s condensed consolidated financial statements. All of the

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business —SelectQuote, Inc. (together with its subsidiaries, the “Company” or “SelectQuote”) contracts with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. The Company obtains leads from, among other sources, InsideResponse, a wholly-owned subsidiary that provides sales leads to the consumer insurance industry. The Company also coordinates various healthcare-related services through its Population Health platform, which includes SelectRx, a closed-door, long-term care pharmacy that offers pharmacy services, including essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services under the Patient Centered Pharmacy Home (PCPH) model. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products, and along with Population Health and InsideResponse, is referred to as “Senior”. SelectQuote’s Life division (“Life”) sells term life, final expense, and other ancillary products, and SelectQuote’s Auto & Home division (“Auto & Home”) primarily sells non-commercial auto and home property and casualty insurance products. SelectQuote’s licensed insurance agents provide comparative rates from a variety of insurance carriers relying on our technology distribution channel with a combination of proprietary and commercially available software to perform its quote service and sell insurance policies on behalf of the insurance carriers. The Company primarily earns revenue in the form of commission payments from the insurance carriers. Commission payments are received both when the initial policy is sold (“first year”) and when the underlying policyholder renews their policy in subsequent years (“renewal”). The Company also receives certain volume-based bonuses from some carriers on first-year policies sold based on attaining various predetermined target sales levels or other agreed upon objectives. These bonuses are referred to as “production bonuses” or “marketing development funds.” Additionally, the Company earns revenue from its Population Health platform, mail-order prescription revenue from SelectRx, and lead generation revenue from InsideResponse.
Basis of Presentation	Basis of Presentation —The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC (“SQAH”), ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC, and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our A nnual Report on Form 10-K for the year ended June 30, 2021, as amended by the Form 10-K/A filed with the SEC on February 14, 2022 (the “2021 Annual Report”) and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2022, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2021. Certain reclassifications have been made to prior periods to conform with current year presentation.
Use of Estimates	Use of Estimates —The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of revenue recognition, accounts receivable, commissions receivable, the provision for income taxes, share-based
Going Concern	Going Concern —The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. Under the Senior Secured Credit Facility, the Company is required to maintain a certain asset coverage ratio, as discussed further in Note 7 to the condensed consolidated financial statements. As of March 31, 2022, the Company is in compliance with all of its debt covenants; however, our financial projections indicate that, based on our current business plan, we will not maintain the required asset coverage ratio within one year after the date that the condensed consolidated financial statements are issued. Failure to maintain the required ratio would constitute a violation of our obligations under the Senior Secured Credit Facility and would permit our lenders to declare us in default. In the event of a default, our lenders could accelerate all amounts owing under the Senior Secured Credit Facility. We do not currently have sufficient liquidity to repay such indebtedness. We have commenced discussions of a covenant waiver or modification with our lenders; however, the Company cannot provide any assurances that it will be successful in obtaining such a waiver or modification on acceptable terms, or at all. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Seasonality	Seasonality —Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period (“AEP”), which runs from October through December each year, and are allowed to switch plans from an existing plan during the open enrollment period (“OEP”), which runs from January through March each year. As a result, commission revenue for our Senior segment is highest in the second quarter and to a lesser extent, the third quarter during OEP. Most policies sold during AEP are effective as of and renew annually on January 1.
Recent Accounting Pronouncements Not Yet Adopted and Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Not Yet Adopted —In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if the acquirer had originated the contracts. Prior to this ASU, an acquirer generally recognizes contract assets acquired and contract liabilities assumed that arose from contracts with customers at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of the amendment (or if adopted early as of an interim period, as of the beginning of the fiscal year that includes the interim period of early application). The Company will continue to evaluate the impact of this guidance, which will depend on the contract assets and liabilities acquired in future business combinations. Recent Accounting Pronouncements Adopted —In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies and changes the accounting for certain income tax transactions, among other minor improvements. This standard was effective for the Company on July 1, 2021, and did not have a material impact on the condensed consolidated financial statements and related disclosures.

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following tables reflect the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated financial statements presented in this Form 10-Q: CORRECTED CONDENSED CONSOLIDATED BALANCE SHEET (unaudited) June 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Accounts receivable $ 113,375 $ (8,077) $ 105,298 Total current assets 493,435 (8,077) 485,358 Total assets 1,433,872 (8,077) 1,425,795 Deferred income taxes 140,988 (1,748) 139,240 Total liabilities 758,983 (1,748) 757,235 Retained earnings (accumulated deficit) 128,254 (6,329) 121,925 Total shareholders’ equity 674,889 (6,329) 668,560 Total liabilities and shareholders’ equity $ 1,433,872 $ (8,077) $ 1,425,795 CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended March 31, 2021 Nine Months Ended March 31, 2021 (in thousands) As Previously Reported Adjustment As Corrected As Previously Reported Adjustment As Corrected Commission revenue $ 236,793 $ (1,577) $ 235,216 $ 664,312 $ (3,681) $ 660,631 Total revenue 266,923 (1,577) 265,346 749,366 (3,681) 745,685 Income (loss) from operations 54,683 (1,577) 53,106 186,111 (3,681) 182,430 Income (loss) before income tax expense (benefit) 43,664 (1,577) 42,087 160,353 (3,681) 156,672 Income tax expense (benefit) 7,183 (331) 6,852 32,619 (773) 31,846 Net income (loss) 36,481 (1,246) 35,235 127,734 (2,908) 124,826 Net income (loss) per share: Basic 0.22 (0.01) 0.21 0.79 (0.02) 0.77 Diluted 0.22 (0.01) 0.21 0.77 (0.02) 0.75 Comprehensive income (loss) $ 38,291 $ (1,246) $ 37,045 $ 129,403 $ (2,908) $ 126,495 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Three Months Ended March 31, 2021 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-December 31, 2020 $ 88,461 $ 634,135 Net Income 36,481 36,481 BALANCES-March 31, 2021 124,942 670,515 Adjustments BALANCES-December 31, 2020 (3,165) (3,165) Net Loss (1,246) (1,246) BALANCES-March 31, 2021 (4,411) (4,411) As Corrected BALANCES-December 31, 2020 85,296 630,970 Net Income 35,235 35,235 BALANCES-March 31, 2021 $ 120,531 $ 666,104 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Nine Months Ended March 31, 2021 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-June 30, 2020 $ (2,792) $ 545,689 Net Income 127,734 127,734 BALANCES-March 31, 2021 124,942 670,515 Adjustments BALANCES-June 30, 2020 (1,503) (1,503) Net Loss (2,908) (2,908) BALANCES-March 31, 2021 (4,411) (4,411) As Corrected BALANCES-June 30, 2020 (4,295) 544,186 Net Income 124,826 124,826 BALANCES-March 31, 2021 $ 120,531 $ 666,104 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited) Nine Months Ended March 31, 2021 (in thousands) As Previously Reported Adjustment As Corrected Net income (loss) $ 127,734 $ (2,908) $ 124,826 Deferred income taxes 32,475 (773) 31,702 Accounts receivable (52,905) 3,681 (49,224) Net cash used in operating activities $ (60,947) $ — $ (60,947)

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Fair Value Hierarchy	The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability
Summary of Total Consideration of the Acquisition	Under the terms of the Asset Purchase Agreement, the total consideration for the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 30,000 Net working capital true-up (499) Total Purchase Consideration $ 29,501 Under the terms of the Stock Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 20,000 Net working capital true-up (483) Closing cash 20 Total purchase consideration $ 19,537 Under the terms of the Membership Interest Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 7,000 Net working capital true-up 347 Closing cash 61 Total purchase consideration $ 7,408
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Accounts receivable $ 1,301 Total tangible assets acquired 1,301 Non-compete agreements 5 years 1,000 Vendor relationships 9 years 23,700 Goodwill Indefinite 3,500 Total intangible assets acquired 28,200 Net Assets Acquired $ 29,501 The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 20 Accounts receivable 613 Other current assets 28 Property and equipment, net 287 Accounts payable (280) Accrued expenses, including compensation and benefits (45) Net tangible assets acquired 623 Proprietary Software 3 years 550 Non-compete agreements 5 years 100 Customer relationships 1 year 200 Goodwill Indefinite 18,064 Total intangible assets acquired 18,914 Net assets acquired $ 19,537 The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 61 Accounts receivable 634 Other current assets 474 Property and equipment, net 415 Accounts payable (259) Net tangible assets acquired 1,325 Customer relationships 1 year 370 Goodwill Indefinite 5,713 Total intangible assets acquired 6,083 Net assets acquired $ 7,408

Property And Equipment_Net (Tab

Property And Equipment—Net (Tables)	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment—net consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Computer hardware $ 25,405 $ 13,351 Machinery and equipment (1) 8,883 2,667 Leasehold improvements 19,276 18,525 Furniture and fixtures 4,623 5,004 Work in progress 11,200 7,220 Total 69,387 46,767 Less accumulated depreciation (23,829) (17,257) Property and equipment—net $ 45,558 $ 29,510 (1) Includes financing lease right-of-use assets.

Software_Net (Tables)

Software—Net (Tables)	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Capitalized Software	Software—net consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Software $ 24,147 $ 16,530 Work in progress 3,658 3,826 Total 27,805 20,356 Less accumulated amortization (12,247) (7,745) Software—net $ 15,558 $ 12,611

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Goodwill	For the following acquisitions, the reporting units to which goodwill has been assigned and the associated reportable segments are as follows: Acquisition Reporting Unit Reportable Segment Auto & Home-controlling interest Auto & Home Auto & Home InsideResponse Senior Senior Lead distribution company Senior Senior Express Med Pharmaceuticals Senior Senior Simple Meds Senior Senior
Schedule of Intangible Assets and Goodwill	The carrying amounts, accumulated amortization, net carrying value, and weighted average remaining life of our definite-lived amortizable intangible assets as well as our goodwill are presented in the tables below (dollars in thousands, useful life in years): March 31, 2022 June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Total intangible assets subject to amortization Customer relationships $ 17,492 $ (5,542) $ 11,950 $ 17,122 $ (3,448) $ 13,674 Trade name 2,680 (1,027) 1,653 2,680 (625) 2,055 Proprietary software 1,592 (719) 873 1,592 (382) 1,210 Non-compete agreements 1,292 (374) 918 1,292 (163) 1,129 Vendor relationships 23,700 (3,072) 20,628 23,700 (1,098) 22,602 Total intangible assets $ 46,756 $ (10,734) $ 36,022 6.4 $ 46,386 $ (5,716) $ 40,670 7.1 Total indefinite-lived assets Goodwill-Auto & Home $ 5,364 $ 5,364 Goodwill-Senior 68,368 62,655 Total goodwill $ 73,732 $ 68,019
Schedule of Goodwill	Changes in the balance of goodwill for the nine months ended March 31, 2022, are as follows (in thousands): Balance, June 30, 2021 $ 68,019 Goodwill from the acquisition of Simple Meds 5,713 Balance, March 31, 2022 $ 73,732
Schedule of Future Amortization Expense	As of March 31, 2022, expected amortization expense in future fiscal periods is as follows (in thousands): Trade Name Proprietary Software Non-compete agreements Vendor Relationships Customer relationships Total Remainder fiscal 2022 $ 134 $ 96 $ 71 $ 660 $ 690 $ 1,651 2023 536 339 273 2,633 2,385 6,166 2024 536 308 220 2,633 2,319 6,016 2025 447 130 220 2,633 2,316 5,746 2026 — — 134 2,633 2,313 5,080 Thereafter — — — 9,436 1,927 11,363 Total $ 1,653 $ 873 $ 918 $ 20,628 $ 11,950 $ 36,022

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Lease Costs and Supplemental Information	The components of lease costs were as follows periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Finance lease costs (1) $ 48 $ 69 $ 132 $ 194 Operating lease costs (2) 1,998 1,980 6,056 5,859 Short-term lease costs 40 42 69 168 Variable lease costs (3) 227 201 696 915 Sublease income (23) (403) (488) (638) Total net lease costs $ 2,290 $ 1,889 $ 6,465 $ 6,498 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.
Schedule of Maturity of Operating Lease Liabilities	Maturities of Lease Liabilities —As of March 31, 2022, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 2,212 57 2,269 2023 8,710 147 8,857 2024 9,032 38 9,070 2025 9,203 38 9,241 2026 7,040 38 7,078 2027 5,666 32 5,698 Thereafter 12,885 — 12,885 Total undiscounted lease payments 54,748 350 55,098 Less: interest 14,266 30 14,296 Present value of lease liabilities $ 40,482 $ 320 $ 40,802
Schedule of Maturity of Finance Lease Liabilities	Maturities of Lease Liabilities —As of March 31, 2022, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 2,212 57 2,269 2023 8,710 147 8,857 2024 9,032 38 9,070 2025 9,203 38 9,241 2026 7,040 38 7,078 2027 5,666 32 5,698 Thereafter 12,885 — 12,885 Total undiscounted lease payments 54,748 350 55,098 Less: interest 14,266 30 14,296 Present value of lease liabilities $ 40,482 $ 320 $ 40,802

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt consisted of the following: (in thousands) March 31, 2022 June 30, 2021 Term Loans $ 470,732 $ 471,912 DDTL Facility 244,388 — Unamortized debt issuance costs (3,163) (4,081) Unamortized debt discount (5,402) (6,428) Total debt 706,555 461,403 Less current portion of long-term debt: (7,169) (2,360) Long-term debt $ 699,386 $ 459,043

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Stock by Class	As of March 31, 2022, the Company has reserved the following authorized, but unissued, shares of common stock: Employee Stock Purchase Plan 877,092 Stock awards outstanding under 2020 Plan 4,752,141 Stock awards available for grant under 2020 Plan 9,571,645 Options outstanding under 2003 Plan 1,701,424 Total 16,902,302
Schedule of Share-Based Compensation Activity	Total share-based compensation for stock awards included in general and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Share-based compensation related to: Equity classified stock options $ 805 $ 451 $ 2,429 $ 1,269 Equity classified RSU's 993 648 3,073 1,608 Equity classified PSU's 231 190 318 512 Total $ 2,029 $ 1,289 $ 5,820 $ 3,389
Schedule of Stock Options, Valuation Assumptions	The Company used the following weighted-average assumptions for the stock options granted during the periods presented below: Nine Months Ended March 31, 2022 2021 Volatility 36.0% 25.0% Risk-free interest rate 1.4% 0.4% Dividend yield —% —% Assumed forfeitures —% —% Expected term (in years) 6.25 6.24 Weighted-average fair value (per share) $3.36 $4.89
Schedule of Stock Options Roll Forward	The following table summarizes stock option activity under the Stock Plans for the nine months ended March 31, 2022: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Outstanding—June 30, 2021 3,398,513 $ 8.60 Options granted 2,460,675 10.23 Options exercised (350,222) 3.74 Options forfeited/expired/cancelled (122,994) 17.81 Outstanding—March 31, 2022 5,385,972 $ 9.45 7.27 $ 3,449 Vested and exercisable—March 31, 2022 2,005,527 $ 3.93 3.94 $ 3,140
Schedule of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the nine months ended March 31, 2022: Number of Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 356,285 $ 19.12 Granted 505,729 15.42 Vested (84,348) 19.72 Forfeited (37,324) 17.86 Unvested as of March 31, 2022 740,342 $ 16.59
Schedule of Performance Stock Activity	The following table summarizes performance stock unit activity under the 2020 Stock Plan for the nine months ended March 31, 2022: Number of Performance Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 (1) 132,921 $ 17.97 Granted (1) 196,080 17.80 Vested — — Forfeited (1,750) 17.89 Performance adjustment (2) (163,626) Unvested as of March 31, 2022 163,625 $ 17.87 (1) Reflects PSU’s at 100% achievement of predefined financial performance targets. If performance metrics are met, PSU’s will vest, at the end of a three-year performance period. The number of shares that could be earned for the fiscal year 2021 tranche will range from 0% to 150% of the target, and the number of shares that could be earned for the fiscal year 2022 tranche will range from 0% to 200% of the target. (2) Represents adjustments to previously granted PSU’s to reflect changes in estimates of future financial performance against targets.

Revenue from Contracts with Cus

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Senior: Commission revenue: Medicare advantage $ 176,603 $ 181,040 $ 355,949 $ 493,745 Medicare supplement 912 2,981 4,849 23,716 Prescription drug plan 393 449 1,393 2,166 Dental, vision, and health 4,150 4,671 12,285 13,041 Other commission revenue 1,415 619 4,269 1,822 Total commission revenue 183,473 189,760 378,745 534,490 Production bonus and other revenue 49,699 25,840 118,714 69,819 Total Senior revenue 233,172 215,600 497,459 604,309 Life: Commission revenue: Term 15,779 19,777 48,151 59,549 Final expense 19,626 20,088 55,100 46,362 Total commission revenue 35,405 39,865 103,251 105,911 Production bonus and other revenue 3,995 4,958 16,361 16,006 Total Life revenue 39,400 44,823 119,612 121,917 Auto & Home: Total commission revenue 6,539 5,910 19,187 21,014 Production bonus and other revenue 613 1,063 1,568 2,738 Total Auto & Home revenue 7,152 6,973 20,755 23,752 Eliminations: Total commission revenue (2,879) (319) (5,689) (784) Production bonus and other revenue (1,732) (1,731) (4,516) (3,509) Total Elimination revenue (4,611) (2,050) (10,205) (4,293) Total commission revenue 222,538 235,216 495,494 660,631 Total production bonus and other revenue 52,575 30,130 132,127 85,054 Total revenue $ 275,113 $ 265,346 $ 627,621 $ 745,685
Schedule of Activity in Commissions Receivable	A roll forward of commissions receivable (current and long term) is shown below for the nine months ended March 31, 2022: (in thousands) Balance as of June 30, 2021 $ 845,897 Commission revenue from revenue recognized 318,399 Net commission revenue adjustment from change in estimate (157,368) Amounts recognized as accounts receivable (168,632) Balance as of March 31, 2022 $ 838,296

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of net income (loss) per share for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands, except per share amounts) 2022 2021 2022 2021 Basic: Numerator: Net income (loss) attributable to common shareholders $ (6,448) $ 35,235 $ (190,609) $ 124,826 Denominator: Weighted-average common stock outstanding 164,083 163,023 163,914 162,705 Net income (loss) per share—basic: $ (0.04) $ 0.21 $ (1.16) $ 0.77 Diluted: Numerator: Net income (loss) attributable to common and common equivalent shareholders $ (6,448) $ 35,235 $ (190,609) $ 124,826 Denominator: Weighted-average common stock outstanding 164,083 163,023 163,914 162,705 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP (1) — 2,708 — 2,790 Total common and common equivalent shares outstanding 164,083 165,731 163,914 165,495 Net income (loss) per share—diluted: $ (0.04) $ 0.21 $ (1.16) $ 0.75 (1) Excluded from the computation of net income (loss) per share-diluted for the three and nine months ended March 31, 2022, because the effect would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted for the periods presented because including them would have been anti-dilutive are as follows for the periods presented: Three Months Ended March 31, Nine Months Ended March 31, (in thousands) 2022 2021 2022 2021 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP 5,393 322 5,069 918 Shares subject to outstanding PSU's (1) 164 132 219 117 Total 5,557 454 5,288 1,035 (1) The weighted-average number of shares excluded from the computation of net income (loss) per share-diluted because the performance conditions associated with these awards were not met.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents information about the reportable segments for the three months ended March 31, 2022: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 233,172 $ 39,400 $ 7,152 $ (4,611) $ 275,113 Operating expenses (200,990) (41,288) (6,002) (13,819) (1) (262,099) Other expenses, net — — — (23) (23) Adjusted EBITDA $ 32,182 $ (1,888) $ 1,150 $ (18,453) 12,991 Share-based compensation expense (2,143) Non-recurring expenses (2) (703) Depreciation and amortization (6,679) Loss on disposal of property, equipment, and software, net (384) Interest expense, net (12,179) Income tax benefit 2,649 Net loss $ (6,448) (1) Operating expenses in the Corp & Elims division primarily include $12.0 million in salaries and benefits for certain general, administrative, and IT related departments, and $4.1 million in professional services fees. (2) These expenses primarily consist of costs related to the change in administrative agent with respect to the Senior Secured Credit Facility and severance expenses. The following table presents information about the reportable segments for the three months ended March 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 215,600 $ 44,823 $ 6,973 $ (2,050) $ 265,346 Operating expenses (140,111) (43,225) (5,877) (12,507) (1) (201,720) Other expenses, net — — — (15) (15) Adjusted EBITDA $ 75,489 $ 1,598 $ 1,096 $ (14,572) 63,611 Share-based compensation expense (1,429) Non-recurring expenses (2) (4,667) Fair value adjustments to contingent earnout obligations (334) Depreciation and amortization (4,323) Loss on disposal of property, equipment, and software (101) Interest expense, net (7,355) Loss on extinguishment of debt (3,315) Income tax expense (6,852) Net income $ 35,235 (1) Operating expenses in the Corp & Elims division primarily include $9.8 million in salaries and benefits for certain general, administrative, and IT related departments and $3.2 million in professional services fees. (2) These expenses primarily consist of costs incurred for the First Amendment, the acquisition of a lead distribution company, re-designation of the hedge, and the Secondary Offering. The following table presents information about the reportable segments for the nine months ended March 31, 2022: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 497,459 $ 119,612 $ 20,755 $ (10,205) $ 627,621 Operating expenses (646,883) (117,347) (16,798) (43,149) (1) (824,177) Other expenses, net — — — (177) (177) Adjusted EBITDA $ (149,424) $ 2,265 $ 3,957 $ (53,531) (196,733) Share-based compensation expense (6,252) Non-recurring expenses (2) (2,857) Depreciation and amortization (17,957) Loss on disposal of property, equipment, and software, net (739) Interest expense, net (31,300) Income tax benefit 65,229 Net loss $ (190,609) (1) Operating expenses in the Corp & Elims division primarily include $33.6 million in salaries and benefits for certain general, administrative, and IT related departments, and $13.1 million in professional services fees. (2) These expenses primarily consist of costs incurred for the Second Amendment, costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds, costs related to the change in administrative agent with respect to the Senior Secured Credit Facility, and severance expenses. The following table presents information about the reportable segments for the nine months ended March 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 604,309 $ 121,917 $ 23,752 $ (4,293) $ 745,685 Operating expenses (385,363) (105,532) (16,889) (34,771) (1) (542,555) Other expenses, net — — — (58) (58) Adjusted EBITDA $ 218,946 $ 16,385 $ 6,863 $ (39,122) 203,072 Share-based compensation expense (3,689) Non-recurring expenses (2) (5,490) Fair value adjustments to contingent earnout obligations (1,487) Depreciation and amortization (11,260) Loss on disposal of property, equipment, and software (261) Interest expense, net (20,898) Loss on extinguishment of debt (3,315) Income tax expense (31,846) Net income $ 124,826 (1) Operating expenses in the Corp & Elims division primarily include $24.8 million in salaries and benefits for certain general, administrative, and IT related departments and $9.5 million in professional services fees. (2) These expenses primarily consist of costs incurred for the First Amendment, the acquisition of a lead distribution company, re-designation of the hedge, and the Secondary Offering as well as non-recurring compensation to a former executive, severance expenses, and expenses related to business continuity in response to the COVID-19 pandemic.

Summary of Business and Signi_4

Summary of Business and Significant Accounting Policies - Revised Balance Sheet and Statements of Comprehensive Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	$ 168,735			$ 168,735		$ 105,298
Total assets	458,498			458,498		485,358
Assets	1,435,314			1,435,314		1,425,795
Deferred income taxes	76,806			76,806		139,240
Total liabilities	938,722			938,722		757,235
Retained earnings (accumulated deficit)	(68,684)			(68,684)		121,925
Total shareholders’ equity	496,592		$ 666,104	496,592	$ 666,104	668,560	$ 544,186	$ 492,404	$ 630,970
Total liabilities and shareholders’ equity	1,435,314			1,435,314		1,425,795
Total revenue	275,113		265,346	627,621	745,685
Income (loss) from operations	3,105		53,106	(224,361)	182,430
Income (loss) before income tax expense (benefit)	(9,097)		42,087	(255,838)	156,672
Income tax expense (benefit)	(2,649)		6,852	(65,229)	31,846
Net income (loss)	$ (6,448)		$ 35,235	$ (190,609)	$ 124,826
Basic (in dollars per share)	$ (0.04)		$ 0.21	$ (1.16)	$ 0.77
Diluted (in dollars per share)	$ (0.04)		$ 0.21	$ (1.16)	$ 0.75
COMPREHENSIVE INCOME	$ 1,141		$ 37,045	$ (181,251)	$ 126,495
Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	39,400		44,823	119,612	121,917
Final expense | Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	19,626		20,088	55,100	46,362
Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	222,538		235,216	495,494	660,631
Commission | Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	$ 35,405		39,865	$ 103,251	105,911
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable						113,375
Total assets						493,435
Assets						1,433,872
Deferred income taxes						140,988
Total liabilities						758,983
Retained earnings (accumulated deficit)						128,254
Total shareholders’ equity			670,515		670,515	674,889	545,689		634,135
Total liabilities and shareholders’ equity						1,433,872
Total revenue			266,923		749,366
Income (loss) from operations			54,683		186,111
Income (loss) before income tax expense (benefit)			43,664		160,353
Income tax expense (benefit)			7,183		32,619
Net income (loss)			$ 36,481		$ 127,734
Basic (in dollars per share)			$ 0.22		$ 0.79
Diluted (in dollars per share)			$ 0.22		$ 0.77
COMPREHENSIVE INCOME			$ 38,291		$ 129,403
As Previously Reported | Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue			236,793		664,312
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable						(8,077)	(2,000)
Total assets						(8,077)
Assets						(8,077)
Deferred income taxes						(1,748)
Total liabilities						(1,748)
Retained earnings (accumulated deficit)						(6,329)
Total shareholders’ equity			(4,411)		(4,411)	(6,329)	(1,503)		$ (3,165)
Total liabilities and shareholders’ equity						(8,077)
Total revenue			(1,577)		(3,681)
Income (loss) from operations			(1,577)		(3,681)
Income (loss) before income tax expense (benefit)			(1,577)		(3,681)
Income tax expense (benefit)			(331)		(773)
Net income (loss)			$ (1,246)		$ (2,908)	(4,800)
Basic (in dollars per share)			$ (0.01)		$ (0.02)
Diluted (in dollars per share)			$ (0.01)		$ (0.02)
COMPREHENSIVE INCOME			$ (1,246)		$ (2,908)
Adjustment | Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue		$ (2,400)	$ (1,577)		$ (3,681)	$ (6,100)	$ (2,000)

Summary of Business and Signi_5

Summary of Business and Significant Accounting Policies - Revised Equity Statements and Note 10 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 492,404	$ 630,970	$ 668,560	$ 544,186	$ 544,186
Net income (loss)	(6,448)	35,235	(190,609)	124,826
Ending balance	496,592	666,104	496,592	666,104	668,560
Deferred income taxes			(65,623)	31,702
Accounts receivable			(62,803)	(49,224)
Net cash used in operating activities			(284,362)	(60,947)
As Previously Reported
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		634,135	674,889	545,689	545,689
Net income (loss)		36,481		127,734
Ending balance		670,515		670,515	674,889
Deferred income taxes				32,475
Accounts receivable				(52,905)
Net cash used in operating activities				(60,947)
Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		(3,165)	(6,329)	(1,503)	(1,503)
Net income (loss)		(1,246)		(2,908)	(4,800)
Ending balance		(4,411)		(4,411)	(6,329)
Deferred income taxes				(773)
Accounts receivable				3,681
Net cash used in operating activities				0
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(62,236)	85,296	121,925	(4,295)	(4,295)
Net income (loss)	(6,448)	35,235	(190,609)	124,826
Ending balance	$ (68,684)	120,531	$ (68,684)	120,531	121,925
Accumulated Deficit | As Previously Reported
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		88,461		(2,792)	(2,792)
Net income (loss)		36,481		127,734
Ending balance		124,942		124,942
Accumulated Deficit | Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		(3,165)		(1,503)	$ (1,503)
Net income (loss)		(1,246)		(2,908)
Ending balance		$ (4,411)		$ (4,411)

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Thousands	Aug. 31, 2021USD ($)	Apr. 30, 2021USD ($)patientsegmentprovision	Feb. 01, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Business Acquisition [Line Items]
Fair value adjustments to contingent earnout obligations					$ 334		$ 0	$ 1,487
Weighted-Average Remaining Useful Life							6 years 4 months 24 days	7 years 1 month 6 days
Lead Distribution Company
Business Acquisition [Line Items]
Purchase consideration, net			$ 33,500
Base purchase price			30,000
Payments to acquire businesses, gross			24,000
Holdback for indemnification claims			6,000
Contingent consideration, liability			3,500
Fair value adjustments to contingent earnout obligations			400
Remaining holdback for indemnification claims				$ (5,500)
Net working capital true-up			499	500
Aggregate purchase price			$ 29,501
Lead Distribution Company | Senior
Business Acquisition [Line Items]
Business acquisition, goodwill, expected tax deductible amount				1,600		$ 1,600	$ 1,600
Lead Distribution Company | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			5 years
Lead Distribution Company | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			9 years
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Base purchase price		$ 20,000
Holdback for indemnification claims		2,500
Contingent consideration, liability		4,000
Fair value adjustments to contingent earnout obligations		300
Net working capital true-up		$ 483
Business acquisition, goodwill, expected tax deductible amount				16,300		16,300	16,300
Net working capital true-up time period		15 months
Percentage of voting interests acquired		100.00%
Aggregate purchase price		$ 24,000
Cash acquired from acquisition		$ 17,500
Number of provisions | provision		2
Consideration arrangements provision one		$ 3,000
Contingent consideration provision one period		20 months
Contingent consideration provision one, minimum number of patients processed | segment		75,000
Contingent consideration provision two		$ 1,000
Contingent consideration, number of active patients | patient		15,000
Contingent consideration provision two period		36 months
Capacity of new facility | segment		75,000
Express Med Pharmaceutical Inc | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		1 year
Express Med Pharmaceutical Inc | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		5 years
Simple Meds
Business Acquisition [Line Items]
Base purchase price	$ 7,000
Payments to acquire businesses, gross	7,000
Net working capital true-up	(347)
Business acquisition, goodwill, expected tax deductible amount				$ 5,600		5,600	$ 5,600
Aggregate purchase price	$ 7,408
Revenue generated from business acquisition						$ 8,600

Acquisitions - Consideration (D

Acquisitions - Consideration (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Apr. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Total purchase consideration			$ 6,927	$ 23,879
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Base purchase price		$ 20,000
Net working capital true-up		(483)
Closing cash		20
Total purchase consideration		19,537
Total purchase consideration		$ 24,000
Simple Meds
Business Acquisition [Line Items]
Base purchase price	$ 7,000
Net working capital true-up	347
Closing cash	61
Total purchase consideration	$ 7,408

Acquisitions - Estimated Fair V

Acquisitions - Estimated Fair Value Of Assets Acquired And Liabilities Assumed (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Apr. 30, 2021	Feb. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Business Acquisition [Line Items]
Goodwill				$ 73,732		$ 68,019
Weighted-Average Remaining Useful Life				6 years 4 months 24 days	7 years 1 month 6 days
Lead Distribution Company
Business Acquisition [Line Items]
Accounts receivable			$ 1,301
Net tangible assets acquired			1,301
Goodwill			3,500
Total intangible assets acquired			28,200
Net assets acquired			$ 29,501
Lead Distribution Company | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			5 years
Lead Distribution Company | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			9 years
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Cash and cash equivalents		$ 20
Accounts receivable		613
Other current assets		28
Property and equipment, net		287
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable		(280)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities		(45)
Net tangible assets acquired		623
Goodwill		18,064
Total intangible assets acquired		18,914
Net assets acquired		$ 19,537
Express Med Pharmaceutical Inc | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		1 year
Express Med Pharmaceutical Inc | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		5 years
Simple Meds
Business Acquisition [Line Items]
Cash and cash equivalents	$ 61
Accounts receivable	634
Other current assets	474
Property and equipment, net	415
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(259)
Net tangible assets acquired	1,325
Goodwill	5,713
Total intangible assets acquired	6,083
Net assets acquired	7,408
Proprietary Software | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 550
Weighted-Average Remaining Useful Life		3 years
Non-compete agreements | Lead Distribution Company
Business Acquisition [Line Items]
Intangible assets			$ 1,000
Weighted-Average Remaining Useful Life			5 years
Non-compete agreements | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 100
Weighted-Average Remaining Useful Life		5 years
Customer relationships | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 200
Weighted-Average Remaining Useful Life		1 year
Customer relationships | Simple Meds
Business Acquisition [Line Items]
Intangible assets	$ 370
Weighted-Average Remaining Useful Life	1 year
Vendor relationships | Lead Distribution Company
Business Acquisition [Line Items]
Intangible assets			$ 23,700
Weighted-Average Remaining Useful Life			9 years

Property And Equipment_Net - Su

Property And Equipment—Net - Summary (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Total	$ 69,387	$ 46,767
Less accumulated depreciation	(23,829)	(17,257)
PROPERTY AND EQUIPMENT—Net	45,558	29,510
Computer hardware
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,405	13,351
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	8,883	2,667
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,276	18,525
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,623	5,004
Work in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 11,200	$ 7,220

Property And Equipment_Net - Na

Property And Equipment—Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 3.3	$ 2	$ 8.4	$ 5.6

Software_Net - Summary (Details

Software—Net - Summary (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Software, gross	$ 27,805	$ 20,356
Less accumulated amortization	(12,247)	(7,745)
SOFTWARE—Net	15,558	12,611
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Software, gross	24,147	16,530
Work in progress
Finite-Lived Intangible Assets [Line Items]
Software, gross	$ 3,658	$ 3,826

Software_Net - Narrative (Detai

Software—Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized software costs in the period	$ 2.2	$ 2.2	$ 6.6	$ 5.4
Capitalized software amortization	$ (1.6)	$ (1)	$ (4.5)	$ (2.7)

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment	$ 0	$ 0	$ 0	$ 0
Amortization of intangible assets	$ 1.7	$ 1.3	$ 5	$ 2.9

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Carrying Amounts of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 46,756		$ 46,386
Accumulated Amortization	(10,734)		(5,716)
Net Carrying Amount	$ 36,022		40,670
Weighted-Average Remaining Useful Life	6 years 4 months 24 days	7 years 1 month 6 days
Goodwill	$ 73,732		68,019
Auto & Home
Finite-Lived Intangible Assets [Line Items]
Goodwill	5,364		5,364
Senior
Finite-Lived Intangible Assets [Line Items]
Goodwill	68,368		62,655
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	17,492		17,122
Accumulated Amortization	(5,542)		(3,448)
Net Carrying Amount	11,950		13,674
Trade Name
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,680		2,680
Accumulated Amortization	(1,027)		(625)
Net Carrying Amount	1,653		2,055
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,592		1,592
Accumulated Amortization	(719)		(382)
Net Carrying Amount	873		1,210
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,292		1,292
Accumulated Amortization	(374)		(163)
Net Carrying Amount	918		1,129
Vendor relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,700		23,700
Accumulated Amortization	(3,072)		(1,098)
Net Carrying Amount	$ 20,628		$ 22,602

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Goodwill Rollforward (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 68,019
Goodwill from the acquisition	5,713
Ending balance	$ 73,732

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Schedule of Future Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	$ 1,651
2023	6,166
2024	6,016
2025	5,746
2026	5,080
Thereafter	11,363
Net Carrying Amount	36,022	$ 40,670
Trade Name
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	134
2023	536
2024	536
2025	447
2026	0
Thereafter	0
Net Carrying Amount	1,653	2,055
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	96
2023	339
2024	308
2025	130
2026	0
Thereafter	0
Net Carrying Amount	873	1,210
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	71
2023	273
2024	220
2025	220
2026	134
Thereafter	0
Net Carrying Amount	918	1,129
Vendor relationships
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	660
2023	2,633
2024	2,633
2025	2,633
2026	2,633
Thereafter	9,436
Net Carrying Amount	20,628	22,602
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	690
2023	2,385
2024	2,319
2025	2,316
2026	2,313
Thereafter	1,927
Net Carrying Amount	$ 11,950	$ 13,674

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 23, 2022
Lessee, Lease, Description [Line Items]
Expected rental payments	$ 54,748	$ 54,748
Leases expected to be commenced	3,500	3,500
Monaca, Pennsylvania | Affiliated Entity
Lessee, Lease, Description [Line Items]
Expected rental payments	$ 3,600	$ 3,600
Operating lease, term	10 years	10 years
Option to extend		5 years
Overland Park, Kansas
Lessee, Lease, Description [Line Items]
Expected sublease income			$ 11,900
Des Moines, Iowa
Lessee, Lease, Description [Line Items]
Loss on lease termination	$ 300
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term	1 year	1 year
Term of lease contract not yet commenced	7 years	7 years
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term	14 years	14 years
Term of lease contract not yet commenced	10 years	10 years

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Finance lease costs	$ 48	$ 69	$ 132	$ 194
Operating lease costs	1,998	1,980	6,056	5,859
Short-term lease costs	40	42	69	168
Variable lease costs	227	201	696	915
Sublease income	(23)	(403)	(488)	(638)
Total net lease costs	$ 2,290	$ 1,889	$ 6,465	$ 6,498

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating leases
Remainder fiscal 2022	$ 2,212
2023	8,710
2024	9,032
2025	9,203
2026	7,040
2027	5,666
Thereafter	12,885
Total undiscounted lease payments	54,748
Less: interest	14,266
Present value of lease liabilities	40,482
Finance leases
Remainder fiscal 2022	57
2023	147
2024	38
2025	38
2026	38
2027	32
Thereafter	0
Total undiscounted lease payments	350
Less: interest	30
Present value of lease liabilities	320
Remainder fiscal 2022	2,269
2023	8,857
2024	9,070
2025	9,241
2026	7,078
2027	5,698
Thereafter	12,885
Total undiscounted lease payments	55,098
Less: interest	14,296
Present value of lease liabilities	$ 40,802

Debt - Credit Agreement and Sen

Debt - Credit Agreement and Senior Secured Credit Facility (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (3,163)	$ (4,081)
Unamortized debt discount	(5,402)	(6,428)
Total debt	706,555	461,403
Less current portion of long-term debt:	(7,169)	(2,360)
Long-term debt	699,386	459,043
Line of Credit | Secured Debt
Debt Instrument [Line Items]
Loans outstanding	$ 470,732	$ 471,912

Debt - Narrative (Details)

Debt - Narrative (Details)	Nov. 05, 2019USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	May 05, 2022USD ($)	Dec. 23, 2021USD ($)	Nov. 02, 2021USD ($)lender	Jun. 30, 2021USD ($)	Feb. 24, 2021USD ($)	May 29, 2020USD ($)
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity								$ 75,000,000
Net proceeds from Term Loans				$ 242,000,000	$ 0
Unamortized debt discount on Term Loans		$ 5,402,000		5,402,000					$ 6,428,000
Unamortized debt issuance costs		22,900,000		22,900,000
Debt issuance costs and debt discounts		27,100,000
Amortization of debt issuance costs		1,200,000	$ 800,000	4,200,000	$ 2,500,000
Cash flow hedge to be reclassified during next 12 months		2,700,000		2,700,000
Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, notional amount											$ 325,000,000
Fair value of interest rate swap		$ 12,300,000		$ 12,300,000
Base Rate | Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, basis spread on variable rate		1.03%		1.03%
Line of Credit | LIBOR
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	5.00%
LIBOR floor rate	0.75%
Line of Credit | Base Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	4.00%
Revolving Credit Facility | LIBOR
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	4.00%
Revolving Credit Facility | Base Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	3.00%
Secured Debt | Line of Credit | Term Loans
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 656,000,000
Debt instrument, periodic payment, percent	1.00%
Secured Debt | Line of Credit | DDTL Facility
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity								200,000,000
Line of credit facility, maximum borrowing capacity		$ 345,000,000		$ 345,000,000						$ 145,000,000
Term loans outstanding		244,388,000		$ 244,388,000					0
Unamortized debt discount on Term Loans								$ 3,000,000
Number of lenders | lender								2
Unamortized debt issuance costs							$ 300,000	$ 1,200,000
Ticking fee multiplier, fee				1.00%
Debt instrument, periodic payment, percent				0.25%
Principal payments made		$ 600,000		$ 600,000
Borrowing covenants time restricted capacity								100,000,000
Secured Debt | Line of Credit | DDTL Facility | Subsequent Event
Line of Credit Facility [Line Items]
Remaining borrowing capacity						$ 100,000,000
Secured Debt | Revolving Credit Facility
Line of Credit Facility [Line Items]
Commitment fee percentage	0.15%
Line of Credit | Base Rate | Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, fixed interest rate		5.00%		5.00%
Line of Credit | Revolving Credit Facility
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity							35,000,000	$ 25,000,000
Line of credit facility, maximum borrowing capacity							$ 135,000,000
Line of Credit | Revolving Credit Facility | Subsequent Event
Line of Credit Facility [Line Items]
Remaining borrowing capacity						$ 135,000,000
Line of Credit | Secured Debt
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity										231,000,000
Line of credit facility, maximum borrowing capacity										$ 425,000,000
Term loans outstanding		$ 470,732,000		$ 470,732,000					$ 471,912,000
Principal payments made		$ 1,200,000		$ 1,200,000

Shareholders' Equity - Common S

Shareholders' Equity - Common Stock Reserved For Future Issuance (Details) - shares	Mar. 31, 2022	Jun. 30, 2021
Class of Stock [Line Items]
Options issued and outstanding under stock option plans (in shares)	5,385,972	3,398,513
Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	16,902,302
Employee Stock Purchase Plan ("ESPP") | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	877,092
2020 Plan | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	9,571,645
Options issued and outstanding under stock option plans (in shares)	4,752,141
2003 Plan | Common Stock
Class of Stock [Line Items]
Options issued and outstanding under stock option plans (in shares)	1,701,424

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Class of Stock [Line Items]
Share-based compensation expense	$ 2,029	$ 1,289	$ 5,820	$ 3,389
Equity classified stock options
Class of Stock [Line Items]
Share-based compensation expense	805	451	2,429	1,269
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Share-based compensation expense	993	648	3,073	1,608
Performance Stock (PSUs)
Class of Stock [Line Items]
Share-based compensation expense	$ 231	$ 190	$ 318	$ 512

Shareholders' Equity - Fair Val

Shareholders' Equity - Fair Value Assumptions (Details) - $ / shares	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Volatility	36.00%	25.00%
Risk-free interest rate	1.40%	0.40%
Dividend yield	0.00%	0.00%
Assumed forfeitures	0.00%	0.00%
Expected term (in years)	6 years 3 months	6 years 2 months 26 days
Weighted-average fair value (in dollars per share)	$ 3.36	$ 4.89

Shareholders' Equity - Option A

Shareholders' Equity - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Mar. 31, 2022
Number of Options
Beginning balance (in shares)	3,398,513
Options granted (in shares)	2,460,675
Options exercised (in shares)	(350,222)
Options forfeited/expired/cancelled (in shares)	(122,994)
Ending balance (in shares)	5,385,972
Vested and exercisable, number of options (in shares)	2,005,527
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 8.60
Options granted (in dollars per share)	10.23
Options exercised (in dollars per share)	3.74
Options forfeited/expired/cancelled (in dollars per share)	17.81
Ending balance (in dollars per share)	9.45
Vested and exercisable, weighted average exercise price (in dollars per share)	$ 3.93
Weighted-average remaining contractual term, outstanding	7 years 3 months 7 days
Weighted-average remaining contractual term, vested and exercisable	3 years 11 months 8 days
Aggregate intrinsic value, outstanding	$ 3,449
Aggregate intrinsic value, vested and exercisable	$ 3,140

Shareholders' Equity - Share-Ba

Shareholders' Equity - Share-Based Compensation Plans (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Cost not yet recognized	$ 10,300		$ 10,300
Cost not yet recognized, period for recognition			3 years 3 days
Proceeds from common stock options exercised and employee stock purchase plan	$ 900	$ 1,400	$ 3,179	$ 1,778

Shareholders' Equity - Restrict

Shareholders' Equity - Restricted Stock Unit and Performance Stock Activity (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Mar. 31, 2022
Restricted Stock Units (RSUs)
Number of Restricted Stock Units
Beginning balance (in shares)	356,285
Granted (in shares)	505,729
Vested (in shares)	(84,348)
Forfeited (in shares)	(37,324)
Ending balance (in shares)	740,342
Weighted-Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 19.12
Granted (in dollars per share)	15.42
Vested (in dollars per share)	19.72
Forfeited (in dollars per share)	17.86
Ending balance (in dollars per share)	$ 16.59
Share-based cost not yet recognized	$ 9.5
Weighted-average remaining service period	2 years 9 months
Performance Stock
Number of Restricted Stock Units
Beginning balance (in shares)	132,921
Granted (in shares)	196,080
Vested (in shares)	0
Forfeited (in shares)	(1,750)
Performance adjustment (in shares)	(163,626)
Ending balance (in shares)	163,625
Weighted-Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 17.97
Granted (in dollars per share)	17.80
Vested (in dollars per share)	0
Forfeited (in dollars per share)	17.89
Ending balance (in dollars per share)	$ 17.87
Share-based cost not yet recognized	$ 1.9
Weighted-average remaining service period	2 years 25 days
Award performance period	3 years
Performance Stock | Share-based Payment Arrangement, Tranche One | Minimum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	0.00%
Performance Stock | Share-based Payment Arrangement, Tranche One | Maximum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	150.00%
Performance Stock | Share-based Payment Arrangement, Tranche Two | Minimum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	0.00%
Performance Stock | Share-based Payment Arrangement, Tranche Two | Maximum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	200.00%

Shareholders' Equity - Employee

Shareholders' Equity - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based compensation expense	$ 2,143	$ 1,429	$ 6,252	$ 3,689
Employee Stock Purchase Plan ("ESPP") | Employee Stock Purchase Plan ("ESPP")
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares issued to employees (in shares)			466,468
Share-based compensation expense	$ 100		$ 400	$ 300

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details)	9 Months Ended
	Mar. 31, 2022installmentplanshares
Class of Stock [Line Items]
Number of share-based compensation plans | plan	2
Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	16,902,302
2003 Plan
Class of Stock [Line Items]
Award exercise period after termination	90 days
Award exercise period after termination due to death or disability	12 months
Award expiration period	10 years
Number of installments | installment	4
Purchase price of common stock, percent	100.00%
2003 Plan | Share-based Payment Arrangement, Tranche One
Class of Stock [Line Items]
Vesting rights percentage	33.30%
2003 Plan | Share-based Payment Arrangement, Tranche Two
Class of Stock [Line Items]
Vesting rights percentage	0.0416%
2020 Plan
Class of Stock [Line Items]
Percentage of outstanding stock annual increase, maximum	3.00%
2020 Plan | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	9,571,645
Incentive Stock Options | 2020 Plan
Class of Stock [Line Items]
Common stock, shares reserved for future issuance (in shares)	4,000,000

Revenue from Contracts with C_2

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 275,113	$ 265,346	$ 627,621	$ 745,685
Commission
Disaggregation of Revenue [Line Items]
Total revenue	222,538	235,216	495,494	660,631
Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	52,575	30,130	132,127	85,054
Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Total revenue	4,611	2,050	10,205	4,293
Intersegment Eliminations | Commission
Disaggregation of Revenue [Line Items]
Total revenue	2,879	319	5,689	784
Intersegment Eliminations | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	1,732	1,731	4,516	3,509
Senior
Disaggregation of Revenue [Line Items]
Total revenue	233,172	215,600	497,459	604,309
Senior | Commission
Disaggregation of Revenue [Line Items]
Total revenue	183,473	189,760	378,745	534,490
Senior | Medicare advantage
Disaggregation of Revenue [Line Items]
Total revenue	176,603	181,040	355,949	493,745
Senior | Medicare supplement
Disaggregation of Revenue [Line Items]
Total revenue	912	2,981	4,849	23,716
Senior | Prescription drug plan
Disaggregation of Revenue [Line Items]
Total revenue	393	449	1,393	2,166
Senior | Dental, vision, and health
Disaggregation of Revenue [Line Items]
Total revenue	4,150	4,671	12,285	13,041
Senior | Other commission revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,415	619	4,269	1,822
Senior | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	49,699	25,840	118,714	69,819
Life
Disaggregation of Revenue [Line Items]
Total revenue	39,400	44,823	119,612	121,917
Life | Commission
Disaggregation of Revenue [Line Items]
Total revenue	35,405	39,865	103,251	105,911
Life | Term
Disaggregation of Revenue [Line Items]
Total revenue	15,779	19,777	48,151	59,549
Life | Final expense
Disaggregation of Revenue [Line Items]
Total revenue	19,626	20,088	55,100	46,362
Life | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	3,995	4,958	16,361	16,006
Auto & Home
Disaggregation of Revenue [Line Items]
Total revenue	7,152	6,973	20,755	23,752
Auto & Home | Commission
Disaggregation of Revenue [Line Items]
Total revenue	6,539	5,910	19,187	21,014
Auto & Home | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	$ 613	$ 1,063	$ 1,568	$ 2,738

Revenues from Contracts with _2

Revenues from Contracts with Customers - Commission Receivable Roll Forward (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Activity in Commissions Receivable [Roll Forward]
Beginning balance	$ 845,897
Commission revenue from revenue recognized	318,399
Net commission revenue adjustment from change in estimate	(157,368)
Amounts recognized as accounts receivable	(168,632)
Ending balance	$ 838,296

Revenues from Contracts with _3

Revenues from Contracts with Customers - Narrative (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2022USD ($)
Disaggregation of Revenue [Line Items]
Net commission revenue adjustment from change in estimate		$ (157,368)
Marketing Development Funds
Disaggregation of Revenue [Line Items]
Unearned revenue	$ 400	400
Medicare advantage | Senior
Disaggregation of Revenue [Line Items]
Net commission revenue adjustment from change in estimate		$ (145,000)
Medicare advantage | Senior | Fiscal Year 2021
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.62
Medicare advantage | Senior | Fiscal Year 2020
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.28
Medicare advantage | Senior | Fiscal Year 2019
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.08

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (2,649)	$ 6,852	$ (65,229)	$ 31,846
Effective income tax rate reconciliation, percent	29.10%	16.30%	25.50%	20.30%

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net income (loss)	$ (6,448)	$ 35,235	$ (190,609)	$ 124,826
Denominator:
Weighted average number of shares outstanding, basic (in shares)	164,083	163,023	163,914	162,705
Net income (loss) per share—basic: (in dollars per share)	$ (0.04)	$ 0.21	$ (1.16)	$ 0.77
Numerator:
Net income (loss) attributable to common shareholders	$ (6,448)	$ 35,235	$ (190,609)	$ 124,826
Denominator:
Weighted average number of shares outstanding, basic (in shares)	164,083	163,023	163,914	162,705
Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP	0	2,708	0	2,790
Total common and common equivalent shares outstanding (in shares)	164,083	165,731	163,914	165,495
Net income (loss) per share—diluted: (in dollars per share)	$ (0.04)	$ 0.21	$ (1.16)	$ 0.75

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Antidilutive Shares (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,557	454	5,288	1,035
Stock Option | Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,393	322	5,069	918
Stock Option | Phantom Share Units (PSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	164	132	219	117

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)segment	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			3
Revenue	$ 275,113	$ 265,346	$ 627,621	$ 745,685
Operating expenses	(262,099)	(201,720)	(824,177)	(542,555)
Other expenses, net	(23)	(15)	(177)	(58)
Adjusted EBITDA	12,991	63,611	(196,733)	203,072
Share-based compensation expense	(2,143)	(1,429)	(6,252)	(3,689)
Non-recurring expenses	(703)	(4,667)	(2,857)	(5,490)
Fair value adjustments to contingent earnout obligations		(334)	0	(1,487)
Depreciation and amortization	(6,679)	(4,323)	(17,957)	(11,260)
Loss on disposal of property, equipment, and software, net			(739)	(261)
Interest expense, net	(12,179)	(7,355)	(31,300)	(20,898)
Loss on extinguishment of debt	0	(3,315)		(3,315)	$ 0
Income tax benefit	2,649	(6,852)	65,229	(31,846)
NET INCOME (LOSS)	(6,448)	35,235	(190,609)	124,826
Corp & Elims
Segment Reporting Information [Line Items]
Revenue	(4,611)	(2,050)	(10,205)	(4,293)
Operating expenses	(13,819)	(12,507)	(43,149)	(34,771)
Other expenses, net	(23)	(15)	(177)	(58)
Adjusted EBITDA	(18,453)	(14,572)	(53,531)	(39,122)
Salary expense	12,000	9,800	33,600	24,800
Professional fees	4,100	3,200	13,100	9,500
Senior
Segment Reporting Information [Line Items]
Revenue	$ 233,172	$ 215,600	$ 497,459	$ 604,309
Senior | Major Customer One | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	25.00%	25.00%	22.00%	26.00%
Senior | Major Customer Two | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	23.00%	20.00%	18.00%	20.00%
Senior | Major Customer Three | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage			13.00%	15.00%
Senior | Operating Segments
Segment Reporting Information [Line Items]
Revenue	$ 233,172	$ 215,600	$ 497,459	$ 604,309
Operating expenses	(200,990)	(140,111)	(646,883)	(385,363)
Other expenses, net	0	0	0	0
Adjusted EBITDA	32,182	75,489	(149,424)	218,946
Life
Segment Reporting Information [Line Items]
Revenue	$ 39,400	$ 44,823	119,612	121,917
Life | Major Customer One | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	14.00%	15.00%
Life | Operating Segments
Segment Reporting Information [Line Items]
Revenue	$ 39,400	$ 44,823	119,612	121,917
Operating expenses	(41,288)	(43,225)	(117,347)	(105,532)
Other expenses, net	0	0	0	0
Adjusted EBITDA	(1,888)	1,598	2,265	16,385
Auto & Home
Segment Reporting Information [Line Items]
Revenue	7,152	6,973	20,755	23,752
Auto & Home | Operating Segments
Segment Reporting Information [Line Items]
Revenue	7,152	6,973	20,755	23,752
Operating expenses	(6,002)	(5,877)	(16,798)	(16,889)
Other expenses, net	0	0	0	0
Adjusted EBITDA	$ 1,150	$ 1,096	$ 3,957	$ 6,863